

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07H 15/18, C07D 309/10, A61K 31/70	A1	(11) International Publication Number: WO 97/31006 (43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/US97/02950 (22) International Filing Date: 20 February 1997 (20.02.97) (30) Priority Data: 08/604,160 21 February 1996 (21.02.96) US (71) Applicant: GLYCOMED INCORPORATED [US/US]; 860 Atlantic Avenue, Alameda, CA 94501 (US). (72) Inventors: ANDERSON, Mark, B.; 41 Las Cascadas, Orinda, CA 94563 (US). LEVY, Daniel, E.; 1733 Clemens Road, Oakland, CA 94602 (US). TANG, Peng, Cho; 827 Camino Ricardo, Moraga, CA 94556 (US). MUSSER, John, H.; 23 Michael Court, San Carlos, CA 94070 (US). RAO, Narasinga; 38 Ulster Place, Alameda, CA 94501 (US). (74) Agents: TEKANIC, Jeffrey, D. et al.; Lyon & Lyon L.L.P., Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: **SIALYL LEWIS^x MIMETICS CONTAINING NAPHTHYL BACKBONES**

(57) Abstract

Compounds that possess selection binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits binding between those groups and the selectins, such compounds being represented by general structural formula (1).



(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTIONSIALYL LEWIS^x MIMETICS CONTAINING NAPHTHYL BACKBONESField of the Invention

This invention relates generally to the field of medicinal chemistry, and specifically to medicaments that are characterized by their capacity to bind to one or more of the three known selectins: E, L, and P-selectins. The medicaments consist of substituted pseudo-oligosaccharides wherein three chemical moieties are covalently linked in the following order : sialic acid, or an analogue, derivative, or mimic thereof, a naphthyl spacer, and fucose or an analogue, derivative, or mimic thereof. Such medicaments have significant applications for diagnosis or prophylactic or therapeutic treatment of certain diseases including cancer, autoimmunity, and inflammation.

Background of the Invention

A large body of data has been accumulated that establishes a family of receptors, the selectins (LEC-CAMs) in certain diseases including cancer, autoimmunity, and in the inflammatory response. The three known members of this family, L-Selectin (LECAM-1, LAM-1, gp90MEL), E-Selectin (LECAM-2, ELAM-1) and P-Selectin (LECAM-3, GMP-140, PADGEM), each contain a domain with homology to the calcium-dependent lectins (C-lectins), an EGF-like domain, and several complement binding protein-like domains (Bevilacqua et al., Science (1989) 243:1160-1165; Johnston et al., Cell (1989) 56:1033-1044; Lasky et al., Cell (1989) 56:1045-1055; Tedder et al., J. Exp. Med. (1989) 170:123-133, Dasgupta et al., Exp. Opin. Invest. Drugs (1994) 3(7):709). It has been proposed that the selectins bind to particular ligands and that this accounts for their biological activity. Thus, drugs that interfere with or prevent binding of the ligands to the selectins will be useful medicaments for treating a variety of diseases.

For instance, adhesion of circulating neutrophils to stimulated vascular endothelium is a primary event of the inflammatory response. Recently, Buerke et al. have demonstrated the important role of selectins in inflammatory states such as ischemia-reperfusion injury in cats (Buerke, M. et al., J. Clin. Invest. (1994) 93:1140). Turunen et al. have demonstrated the role of sLe^x and L-selectin in site-specific lymphocyte extravasation in renal transplants during acute rejection (Turunen, J.P. et al., Eur. J. Immunol. (1994)

24:1130). P-selectin has been shown to be centrally involved particularly as related to acute lung injury. Mulligan et al. have reported strong protective effects using anti-P-selectin antibody in a rodent lung injury model. (Mulligan, M. S. et al., J. Clin. Invest., (1991) 20:1600, Mulligan, M. S. et al., Nature (1993) 364:149). A central role of P-selectin in inflammation and thrombosis has been demonstrated by Palabrica et al. (Palabrica, T. et al., Nature (1992) 359:843).

10 Of the three selectins, E-selectin is particularly interesting because of its transient expression on endothelial cells in response to IL-1 or TNF (Bevilacqua et al., Science (1989) 243:1160). The time course of this induced expression (2-8 h) suggests a role for this receptor in initial neutrophil extravasation in response to infection and injury. Indeed, Gundel et al. have shown that antibody to E-selectin blocks the influx of neutrophils in a primate model of asthma and thus is beneficial for preventing airway obstruction resulting from the inflammatory response. (Gundel R. H. et al., J. Clin. Invest. (1991) 88:1407).

15 20

Several different groups have published papers regarding E-selectin ligands. Lowe et al., (1990) demonstrated a positive correlation between E-selectin dependent adhesion of HL-60 cell variants and transfected cell lines, with their expression of the sialyl Lewis x (sLe^x) oligosaccharide, NeuNAc α -2-3-Gal- β 1-4(Fuc α -1-3)-GlcNAc. By transfecting cells with plasmids containing an α -(1,3/1,4) fucosyltransferase, they were able to convert non-myeloid COS or CHO lines

25 30

into sLe^x-positive cells that bind in an E-selectin dependent manner. Walz et al., (1990) were able to inhibit the binding of an E-selectin-IgG chimera to HL-60 cells with a monoclonal antibody directed against sLe^x or by glycoproteins with the sLe^x structure, but could not demonstrate inhibition with CD65 or CD15 antibodies. Both groups concluded that the sLe^x structure is the ligand for E-selectin.

Information regarding the DNA sequences encoding endothelial cell-leukocyte adhesion molecules are disclosed in PCT published application W090/13300 published November 15, 1990 incorporated herein by reference. The PCT publication cites numerous articles which may be related to endothelial cell-leukocyte adhesion molecules. The PCT publication claims methods of identifying E-selectin ligands, as well as methods of inhibiting adhesion between leukocytes and endothelial cells using such ligands and specifically refers to MILAs which are described as molecules involved in leukocyte adhesion to endothelial cells. Recent publications regarding selectin ligands describe the use of L-selectin as an indicator of neutrophil activation (Butcher et al., U.S. Patent 5,316,913 issued May 31, 1994), and assays for inhibition of leukocyte adhesion (Rosen et al., U.S. Patent 5,318,890 issued June 7, 1994).

As alluded to above, the ligand for E-selectin, sLe^x, consists of at least sialic acid, fucose, and N-acetyl lactosamine. Lactosamine consists of galactose and 2-amino-2-deoxyglucose. Sialic acid and fucose are


bound to the galactose and glucosamine moieties of lactosamine, respectively. Ligands that bind to the other selectins share similar structural features. Considering the obvious medical importance of selectin
5 ligands, significant effort has been, and continues to be expended to identify the critical physical/chemical parameters associated with selectin ligands that enhance, or that are required for their activity (DeFrees, S.A., et al., J. Am. Chem. Soc., (1993)
10 115:7549). In no small part this effort is being driven by the need to have selectin ligands that are inexpensive to produce (see U.S. Patent 5,296,594 issued March 22, 1994; Allanson, N.M. et al., Tetrahedron Lett., (1993) 34:3945; Musser, J.H. et al., Current
15 Pharmaceutical Design (1995) 221-232). It is generally thought that it will be prohibitively expensive to commercially produce naturally occurring sLe^x by either enzymatic or chemical synthesis because of the number of sophisticated reactions involved.

20 The selectin family of adhesion molecules participate in acute inflammation by initiating neutrophil rolling on activated endothelial cells. This is particularly evident in studies of ischemia reperfusion injury, where P-selectin appears to be
25 important in neutrophil recruitment to damaged tissue. The presence of L-selectin and E- or P-selectin ligands on mononuclear cells has implicated these receptor-ligand interactions in chronic inflammation. This has been supported by the finding of chronic
30 expression of E-selectin in dermatologic conditions, and

- P-selectin expression on joint synovial endothelium derived from rheumatoid arthritis patients. L. Lasky Annu. Rev. Biochem. 64:113-39 (1995); "Selectin Family of Adhesion Molecules" by Michael Forrest and James C. Paulson in Physiology and Pathophysiology of Leukocyte Adhesion, Ed. by D. Niel Grangier and Deert Schmid-Schönbein, Oxford University Press, N.Y., N.Y. (1995).

Summary of the Invention

- A first object of the invention is the description of medicaments that are selectin ligand mimetics that bind to certain selectins wherein the mimetics lack the lactose-core structure of the natural selectin ligand, sialyl Lewis^x (sLe^x), and have substituted in its place a naphthyl moiety, relative to sLe^x. Such invention compounds are represented by the following general structural formula I:




(I)

wherein


$R^1, R^2, R^3, R^4, R^5, R^6, R^7$, and R^8 are independently selected from the group consisting of :

- (a) $-H$, $Y-B$, alkyl of 1 to 4 carbon atoms
 5 optionally substituted with 1 to 2 lower alkyl groups,



$-OH$, lower alkoxy, lower aryloxy, lower aralkoxy,

lower alkoxyaryl, amino,



- 10 $CH_2-C\equiv C-B, -N(CH_2-C\equiv C-B)_2, -N(Ac)CH_2Ar-B, -NHCH_2Ar-B,$




$-N(CH_2Ar-B)_2, -OCH_2Ar-B, -(C=O)(CH_2)_m-B,$

(b) a direct link to A and a direct link to B;


where

$Y-B$ is selected from the group consisting of


- 15 $-W(CH_2(C=O)CH_2-B)_t, -W(CH_2(C=C(R^{15})_2)-CH_2-B)_t,$



20



25



30


A is selected from the group consisting of

$-(C=O)R^{11}$, sialic acid, Kemp's acid, quinic acid, $-B$,
 $-SO_3M$, $-OSO_3M$, $-SO_2NH_2$, $-PO_3M'_2$, $-OPO_3M'_2$, $-NO_2$, saturated or
 unsaturated carboxylic acids of 1 to 4 carbon atoms,

optionally substituted with 1 to 2 hydroxyl groups, and esters, and amides thereof;

W is selected from the group consisting of a direct link, -O-, -N<, -S-, -NH-, and -NAC-;

5 B is



wherein-

U is selected from the group consisting of -R⁹, -CH₂OR¹⁰, -CH₂O-protecting group, -COOR¹¹, -CON(R¹²)₂, and -COOM;

10 R⁹ is lower alkyl;

each n is independently selected from the group 0, 1, 2, and 3;

each m is independently selected from the group 0, 1, 2, 3, and 4;

15 each q is independently selected from the group 0, 1, and 2;

each s is independently selected from the group 1, 2, and 3;

20 each z is independently selected from the group 1 and 2;

each t is independently selected from the group 1 and 2, with the proviso that when W is -N<, then t is 2, and at all other definitions of W, t is 1;

R^{10} is selected from the group consisting of -H, $-R^{11}$, $-\text{SO}_3\text{M}$, $-(\text{C}=\text{O})\text{R}^{11}$, $-\text{SO}_2\text{NH}_2$, $-\text{PO}_3\text{M}_2$, $-\text{alk}-\text{COOR}^{11}$, $\text{alk}-\text{CON}(\text{R}^{11})_2$ and -O-carbohydrate;

R^{11} is independently selected from the group
5 consisting of -H, lower alkyl, cyclic alkyl of 5 to 6 carbon atoms, heterocyclic alkyl of 4 to 5 carbon atoms and 1 to 2 heteroatoms, lower aryl and lower aralkyl;

R^{12} is selected from the group consisting of $-\text{N}(\text{R}^{11})_2$, and $-\text{SR}^{11}$;

10 R^{13} is selected from the group consisting of R^{11} , and M;

R^{14} is selected from the group consisting of -H, and $-\text{OR}^{10}$, with the proviso that when z is 2, then together the two R^{14} groups may form a double bond;

15 R^{15} is independently selected from the group consisting of $-\text{R}^{11}$ and $-\text{COOH}$.

M is selected from the group consisting of Na^+ , K^+ , Mg^{2+} , and Ca^{2+} ;

M' is selected from the group consisting of -H, -M,
20 and R^9 ; and

X is selected from the group consisting of -O-, -S-, $-\text{C}(\text{R}^{11})_2-$, and $-\text{N}(\text{R}^{11})-$; and pharmaceutically acceptable salts thereof with the provisos that:

(a) when any of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are
25 -Y-B and W is a direct link, then at least one adjacent position must be -OH or an ether moiety;

(b) no more than two of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 may be Y-B when W is a direct link;

(c) no more than three of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 ,
30 and R^8 may be a direct link to A;

(d) only one of R^1 , R^4 , R^5 , and R^6 may be a direct link to B;

(e) when one of R^1 , R^4 , R^5 , or R^8 is a direct link to B, then at most two of the other naphthyl substituents
5 can be a direct link to A when A is not B;

(f) at most three of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 may be independently selected from the group consisting of -OH and ether moieties;

(g) at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8
10 is -H;

(h) when any of R^1 , R^4 , R^5 , and R^8 is a direct link to B, then the adjacent position must -OH or an ether moiety; -

(i) at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8
15 is a substituent containing a B group, and at least one is a substituent containing an A group where A is not B; and

(j) only when A is directly linked to the naphthyl structure may A be $-(C=O)R^{11}$, and when A is $-(C=O)R^{11}$, at
20 least one adjacent position must be -OH.

A second object of the invention is a description of certain novel medicaments that incorporate newly discovered physical/chemical properties associated with sLe^x , such that the medicaments have a three-
25 dimensionally stable configuration for the presentation of the functional groups of sLe^x , sialic acid and fucose, that facilitates binding between those groups and the selectins.

A third object of the invention is to provide a composition comprising selectin ligand medicaments bound to a detectable label and/or bound to a pharmaceutically active drug such as an anti-inflammatory drug.

5 A fourth object of the invention is to provide a pharmaceutical formulation containing selectin ligand medicaments which is useful in treating certain diseases.

A fifth object of the invention is to provide a
10 description of methods to treat or diagnose disease.

A sixth object of the invention is to provide compositions and methods to determine the site of inflammation by administering labeled formulations of the type referred to above.

15 Another object of the invention is that the ligands can be labeled and the labeled ligands used in an assay to detect the presence of selectins in a sample.


These and other objects, advantages and features of the present invention will become apparent to those
20 persons skilled in the art upon reading the details of the synthesis, structure, formulation and usage as more fully set forth below.

Definitions

In accordance with the present invention and as
25 used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

Sialic acids refer to the family of amino sugars containing 9 or more carbon atoms, N- and O- substituted derivatives of neuraminic acid.

Kemp's acid refers to 1,3,5-trimethyl-1,3,5-cyclohexane-tricarboxylic acid, where each acid is axial. N-acetyl neuraminic acid refers to 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid:



α form refers to standard nomenclature representing the configuration of the anomeric position of an O- or C-glycoside.

β form refers to standard nomenclature representing the configuration of the anomeric position of an O- or C-glycoside.

"Amino" refers to $-NR_2$, where each R is independently selected from -H, lower alkyl, lower aryl, and lower aralkyl.

"Alkyl" refers to saturated hydrocarbons, which may be straight chain, branched, cyclic, or alicyclic. Preferably the alkyl group contains 1 to 10 carbon atoms. Most preferred is 1 to 4 carbon atoms.



"Lower alkyl" refers to branched or straight chain alkyl of 1 to 4 carbon atoms.

"Alkoxy" refers to -OR, where R is an alkyl group.
Lower alkoxy refers to -OR where R is lower alkyl.

"Aryl" refers to aromatic groups which have one
ring having a conjugated pi electron system and includes
5 carbocyclic aryl, and heterocyclic aryl, both of which
may be optionally substituted. Lower aryl refers to an
aryl containing up to 6 carbon atoms, and may be
optionally substituted.

"Carbocyclic aryl" groups are groups wherein the
10 ring atoms are carbon atoms.

"Heterocyclic aryl" groups are groups having from 1
to 2 heteroatoms in the ring and the remainder of the
ring atoms are carbon atoms. Suitable heteroatoms
include nitrogen, oxygen, and sulfur. Suitable
15 heterocyclic aryl groups include pyridyl, furanyl,
thienyl, pyrrolyl, and the like all optionally
substituted. Heteroaryl is the same as heterocyclic
aryl.

"Alicyclic" refers to groups which combine the
20 properties of aliphatic and cyclic alkyl groups. For
example, $-\text{CH}_2-$  and $-\text{CH}_2-$  are alicyclic groups.

The term "optionally substituted" aryl groups
refers to either no substitution or substitution by one
to three substituents independently selected from lower
25 alkyl, halo, carboxylic acids, esters, $-\text{NO}_2$, and lower
perhaloalkyl.

"Aralkyl" refers to an alkyl group substituted with
an aryl group, which may be optionally substituted.
Benzyl is a suitable aralkyl group. Lower aralkyl
30 refers to up to and including 8 carbon atoms, and may be

optionally substituted. The aralkyl group is attached through the alkyl portion of the group.

"Alkenyl" refers to unsaturated groups which contain at least one carbon-carbon double bond and includes straight-chain, branched chain, and cyclic groups. The double bond may be exo to the chain.

"Alkoxyaryl" refers to aryl substituted with alkoxy group.

"Alkynyl" refers to unsaturated groups which contain at least one carbon triple bond and includes straight-chain, branched chain, and cyclic groups.

"Aryloxy" refers to -O-aryl.

"Aralkoxy" refers to -O-aralkyl.

"Carboxylic acid" refers to -COOH.

"Ester" refers to -COOR where R is lower alkyl, lower aryl, and lower aralkyl;

"Amide" refers to -CONR₂ where each R is independently selected from hydrogen, lower alkyl, lower aryl, and lower aralkyl. Preferably at least one R is hydrogen.

"M" refers to a cationic metal selected from Na⁺, K⁺, Mg²⁺, and Ca²⁺. Where M is associated with -COO⁻, it is preferably a plus one cation, and more preferably Na⁺.

"Protecting group" refers to a group protecting one or several inherent functional groups. Suitable "protecting groups" will depend on the functionality and particular chemistry used to construct the library.

Examples of suitable functional protecting groups will be readily apparent to skilled artisans, and are described, for example, in Greene and Wutz, Protecting

Groups in Organic Synthesis, 2d ed., John Wiley & Sons, NY (1991), which is incorporated herein by reference. Suitable -O-protecting groups can be found in the above book. Preferred such protecting groups include acetate
5 and benzyl.

"Carbohydrate" refers to a chemical moiety comprising the general composition $(C)_n(H_2O)_n$, including, but not limited to glucose, galactose, fucose, fructose, saccharose, mannose, arabinose, xylose, sorbose,
10 lactose, and derivatives thereof, including but not limited to compounds which have other elemental compositions, such as aldonic acids, uronic acids, desoxysugars, or which contain additional elements or moieties, such as amino sugars wherein n is typically 4,
15 5, 6, 7 atoms and wherein the oxygen atom in the carbohydrate can be replaced by a heteroatom such as nitrogen, sulfur, carbon etc. A carbohydrate as used herein is understood to include chemical structures wherein "H" of any hydroxy group is replaced by any
20 chemically compatible moiety "R", which can be any monomer, oligomer or polymer in the meaning as used herein. Carbohydrates can be saturated or unsaturated. Carbohydrates may be charged or uncharged. Suitable charged carbohydrates include galacturonic acid,
25 glucuronic acid, and sialic acid.

"Carbohydrate unit" is a monomer comprising a monosaccharide.

"Carbon glycoside" is a carbohydrate derivative wherein the anomeric position does not have an oxygen
30 but a carbon substituent.

"Heteroatom glycoside" is a carbohydrate wherein the oxygen at the anomeric position is replaced by an atom other than oxygen, including carbon, nitrogen, sulfur, phosphorous and silicon.

5 "Identifier tag" is any detectable attribute that provides a means to elucidate the structure of an individual oligomer in a labeled synthetic oligomer library. For example, an identifier tag can be used to identify the resulting products in the synthesis of a
10 labeled synthetic oligomer library.

"Named Reactions" are chemical reactions which are chemical standard reactions known by those of ordinary skill in the art, including but not limited to the Alper Reaction, Barbier Reaction, Claisen-Ireland Reaction,
15 Cope Rearrangement, Delepine Amine synthesis, Gewald Heterocycle Synthesis, Hiyama-Heathcock Stereoselective Allylation, Stork Radical Cyclization, Trost Cyclopentanation, Weidenhagen Imidazole Synthesis. See, in general, Hassner and Stumer, 1994. See, among other
20 places, "Organic Syntheses Based on Named Reactions and Unnamed Reactions", Tetrahedron Organic Chemistry Series, eds. Baldwin and Magnus, Pergamon, Great Britain.

"Cope Reaction" or "Cope" refers to the 3, 3
25 sigmatropic rearrangement and includes the Claisen-Ireland Reaction and all forms of the Cope rearrangement.

"Oligosaccharide" or "polysaccharide" refers to carbohydrates, including carbon glycosides, comprising a
30 plurality of monosaccharides.

"Synthetic chemical library" is a collection of random and semi-random synthetic molecules wherein each member of such library is produced by chemical or enzymatic synthesis.

5 A "Synthesis support" is a material having a rigid or semi-rigid surface and having functional groups or linkers. A synthesis support may be capable of being derivatized with functional groups or linkers that are suitable for carrying out synthesis reactions.


10 Such materials will preferably take the form of small beads, pellets, disks, capillaries, hollow fibers, needles, solid fibers, cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with polyethylene glycol divinylbenzene, grafted
15 co-poly beads, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with a hydrophobic polymer, or other convenient forms.

20 "Transformation event" or "Reaction" is any event that results in a change of chemical structure of a compound, monomer, an oligomer or polymer. A "transformation event" or "reaction" may be mediated by physical, chemical, enzymatic, biological or other
25 means, or a combination of means, including but not limited to, photo, chemical, enzymatic or biologically mediated isomerization or cleavage, photo, chemical, enzymatic or biologically mediated side group or functional group addition, removal or modification,
30 changes in temperature, changes in pressure, and the

like. Thus, "transformation event" or "reaction" includes, but is not limited to, events that result in an increase in molecular weight of a monomer, an oligomer or polymer, such as, for example, addition of one or a plurality of monomers, addition of solvent or gas, or coordination of metal or other inorganic substrates such as, for example, zeolites. A "transformation event" or "reaction" may also result in a decrease in molecular weight of an oligomer or polymer, such as, for example, de-hydrogenation of an alcohol to from an alkene or enzymatic hydrolysis of an ester or amide. "Transformation events" or "reaction" also include events that result in no net change in molecular weight of a monomer, an oligomer or polymer, such as, for example, stereochemistry changes at one or a plurality of a chiral centers, Claissen rearrangement, Ireland rearrangement, or Cope rearrangement and other events as will become apparent to those skilled in the art upon review of this disclosure.

"Heterocyclic alkyl" refers to a cyclic alkyl group in which one to three of the ring atoms are a heteroatom and the remaining ring atoms are carbon atoms. Suitable heteroatoms are nitrogen, oxygen, and sulfur. Suitable heterocyclic alkyl groups are morpholine, piperadine, and piperazine.

"Adjacent position" refers to the next carbon atom on the naphthyl ring. For example, R^3 and R^1 are adjacent to R^2 , in the naphthyl structure depicted below:




R^1 and R^8 are not considered adjacent positions.

5 "Naphthyl structure" refers to the bicyclic aromatic group above.

"Ether moiety" refers to any substituent or group linked through an oxygen. For example, $-O(CH_2)_nB$, $-O(CH_2)_nA$, and $-O(CH_2(C=(R^{11})_2)CH_2-B$, and alkoxy are ether
10 moieties.

"-Ar-" refers to a phenyl, optionally substituted.

"-alk-" refers to an alkyl linking group which is selected from lower alkyl, and cycloalkyl. Suitable
"-alk-" groups include $-C(CH_3)_2-$, and .

15 "Halo" refers to halogen atoms $-F$, $-Cl$, $-Br$, and $-I$.

"Cycloalkyl" refers to cyclic alkyl groups and include cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl.

20 The term "pharmaceutically acceptable salt" includes salts of compounds of formula I derived from the combination of a compound of this invention and an organic or inorganic acid or base. The compounds of

formula I are useful in both the free acid and salt form.

Brief Description of the Drawings

This invention may be better understood and its
5 numerous objects, advantages and features will become apparent to those skilled in the art by reference to the accompanying drawings as follows:

Figure 1 is a cross-sectional schematic view showing the interaction between white blood cells and
10 activated endothelial cells.

Figure 2 is a cross-sectional schematic view showing how compounds of the invention would be used as pharmaceuticals to block selectin ligand interactions.

Detailed Description of the Invention

15 Throughout the description of the invention reference is made to certain publications including scientific articles and patents or patent applications. It is the intent that each of these publications be incorporated by reference in their entirety when
20 referred to in the specification.

Before describing the present invention it is to be understood that this invention is not limited to the particular compositions, methods or processes described as such compositions and methods may, of course, vary.

25 As used in this specification and the appended claims, the singular forms "a", "an" and "the" include the plural unless the context clearly dictates otherwise. Thus, for example, reference to "a tethered

compound" includes mixtures of such compounds, reference to "an E-selectin", "a P-selectin", or "an L-selectin" includes reference to respective mixtures of such molecules, reference to "the formulation" or "the method" includes one or more formulations, methods and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure.

Some standard abbreviations used in connection with the present invention include: BSA, bovine serum albumin; DEAE, diethylaminoethyl; DMSO, dimethylsulfoxide; DMF, N,N-dimethylformamide; DCE, dichloroethane; E-selectin or ELAM-1, endothelial/leukocyte adhesion molecule-1; HPTLC, high performance thin layer chromatography; L-selectin or LECAM-1, leukocyte/endothelial cell adhesion molecule-1; MOPS, 3-(N-Morpholino)-propanesulfonic acid; NANA, N-acetylneuraminic acid; PVC, polyvinylchloride; TLC, thin layer chromatography; TFA, trifluoro-acetic acid; Tris, tris (hydroxy-methyl) aminomethane.


Development of the Invention

It is worth noting that while the invention compounds were selected for their capacity to bind to certain selectins, and that therefore this property contributes to their medical activity, it cannot, however, be excluded that they are also exerting their favorable medical effects, either in parallel or in tandem, through additional mechanisms of action. Thus,

the skilled practitioner of this art will appreciate that a key aspect of the subject invention is the description of novel medicaments, and that Applicants intend not to be bound by a particular mechanism of
5 action that may account for their prophylactic or therapeutic effects.

E-selectin has a lectin like domain that recognizes the Sialyl Lewis x (sLe^x) tetrasaccharide epitope as shown below in Structure III.

10




III

The ability of sLe^x to bind E-selectin is described by Lowe et al., Cell (1990) 63:475; Phillips et al., Science (1990) 250:1130; Walz et al., Science (1990)
15 250:1132; and Tyrrell et al., Proc. Natl. Acad. Sci. USA (1991) 88:10372.

It has also been shown (Berg et al., J. Biol. Chem. (1991) 265:14869; Handa et al., Biochem. Biophys. Res. Commun. (1991) 181:1223) that both E-selectin and P-

selectin recognize the isomeric tetrasaccharide sLe^a shown below as Structure IV.



IV


5 L and P-selectin also bind to sLe^a containing ligands, although these selectins have specificity toward a wider variety of natural ligands containing sialylated and sulfated Le^a, and Le^a structures as well as other sulfated or charged carbohydrates (Varki et al.
10 Proc. Nat'l Acad. Sci. USA 91:7390-7397 (1994)).

A key step in developing the compounds of the present invention was the realization that both sLe^a and sLe^x share a structural similarity in their three dimensional arrangements.

15 Specifically, we observed that sialic acid and fucose, two functional epitopes in these tetrasaccharides, are juxtaposed in space in a way suitable for recognition by the selectins. Most importantly, for both tetrasaccharides we identified 4
20 to 12 atoms associated with the lactose core of the

tetrasaccharides that functionally separate sialic acid from fucose. We postulated that replacement of these atoms would lead to compounds, such as those described and claimed herein, that maintain their selectin binding activity. While 4 to 12 is the preferred number of atoms, most preferred is 6 to 8 atoms as shown in the figure below. The number of atoms refers to the number of atoms between the O-glycoside of sialic acid and the O-glycoside of fucose.

For instance, a close structural examination of sLe^x (shown in III) or a modification thereof wherein R = OH (sLe^xGlc) indicates that the epitopes i.e., α -Neu5Ac and L-Fucose, are linked through six atoms (Nos. 1-6) or eight atoms (Nos. i-viii) as shown in Structure III (a) below



III (a)

wherein R is -NHAc or -OH.

Based on this discovery, we deduced that the corresponding epitopes on the lectin domain of the selectins, are spaced in a similar three-dimensional configuration such that maintenance of the 6 to 8 atoms
5 in the ligand structure would yield active ligands that are markedly different in structure from the naturally occurring ligand.


We have also shown that sLe^x and sLe^a present the fucose and sialic acid functionalities in a special
10 relationship placing them on a single face with a spacing of 10-12Å measured between the carbonyl carbon of the carboxylic acid on sialic acid and the C-3 of fucose. Rao et al. J. Bio. Chem. 269(31):19663 (1994).

The compounds of the present invention possess an
15 acid functionality mimic which is preferably 8-14Å, and more preferably 9-11Å from a fucose or fucose mimic. This distance is measured from the carbonyl carbon of the acid mimic to the C-3 carbon of fucose or its equivalent on its mimic.

20 Additionally, we postulated that replacement of the lactose core with a partially or completely rigid core, while still juxtaposing the two functional epitopes in space in a way suitable for recognition by the selectins, would lead to compounds, such as those
25 described and claimed herein, that maintain their selectin binding activity. The Naphthyl family of compounds offer considerable diversity and facility in terms of attachment of suitable groups to satisfy the spacial requirements for selectin ligand binding.


Using these insights, we then designed certain selectin ligands. This has been done by attaching sialic acid and L-fucose as such, or analogs, suitable derivatives, or mimics thereof, through six or eight
5 atoms to provide a series of compounds shown as structural formula I. This series of compounds is designed to competitively inhibit selectins from binding to their natural ligands. These compounds can be combined with pharmaceutically acceptable excipients to
10 provide pharmaceutical compositions useful in a wide range of treatments.

Applicants believe that the carboxylic acid portion of sialic acid is important for binding. Thus, mimics of sialic acid include moieties containing carboxylic
15 acids, esters and amides. It also includes a vinylagous acid which can mimic the acid functionality, such the group shown below:



Other sialic acid mimics, also referred to as "A" in the
20 general description, can be in the form of moieties containing sulfates, sulfonates, phosphates, phosphonates, sulfonamides, nitrates, other carboxylic acid equivalents, and the like. Other acid mimics include B groups, particularly B groups which contain
25 acids and sulfates.

The compounds of the present invention are designed to provide a three-dimensionally stable configuration for functional groups on sialic acid and fucose moieties or their analogues or mimics so as to allow for binding
 5 between those functional groups and receptors on natural selectins. The compounds are represented by the following general structural formula I:




wherein

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are independently
 10 selected from the group consisting of

(a) -H, Y-B, alkyl of 1 to 4 carbon atoms optionally substituted with 1 to 2 lower alkyl groups,
 $-W((CH_2)_n-B)_c$, $-W((CH_2)_m-(CHR^9)_q-(CH_2)_m-A)_c$;
 -OH, lower alkoxy, lower aryloxy, lower aralkoxy,
 15 lower alkoxyaryl, amino,
 $-W((CH_2)_n-A)_c$, $-O-CH_2-C\equiv C-B$, $-N(Ac)-CH_2-C\equiv C-B$, $-NH-CH_2-C\equiv C-B$, $-N(CH_2-C\equiv C-B)_2$, $-N(Ac)CH_2Ar-B$, $-NHCH_2Ar-B$,
 $-N(CH_2Ar-B)_2$, $-OCH_2Ar-B$, $-(C=O)(CH_2)_m-B$,

(b) a direct link to A, and a direct link to B;
 20 where


Y-B is selected from the group consisting of



A is selected from the group consisting of
 -(C=O)R¹¹, sialic acid, Kemp's acid, quinic acid, -B,
 -SO₃M, -OSO₃M, -SO₂NH₂, -PO₃M₂,
 -OPO₃M₂, -NO₂, saturated or unsaturated carboxylic acids
 of 1 to 4 carbon atoms, optionally substituted with 1 to
 2 hydroxyl groups, and esters, and amides thereof;

W is selected from the group consisting of a direct
 link, -O-, -N-, -S-, -NH-, and -NAC-;

B is



wherein

U is selected from the group consisting of $-R^9$, $-\text{CH}_2\text{OR}^{10}$, $-\text{CH}_2\text{O-protecting group}$, $-\text{COOR}^{11}$, $-\text{CON}(\text{R}^{11})_2$, and $-\text{COOM}$;

R^9 is lower alkyl;

5 each n is independently selected from the group 0, 1, 2, and 3;

each m is independently selected from the group 0, 1, 2, 3, and 4;

10 each q is independently selected from the group 0, 1, and 2;

each s is independently selected from the group 1, 2, and 3;

each z is independently selected from the group 1 and 2;

15 each t is independently selected from the group 1 and 2, with the proviso that when W is $-\text{N}$, then t is 2, and at all other definitions of W, t is 1;

R^{10} is selected from the group consisting of $-\text{H}$, $-\text{R}^{11}$, $-\text{SO}_3\text{M}$, $-(\text{C}=\text{O})\text{R}^{11}$, $-\text{SO}_2\text{NH}_2$, $-\text{PO}_3\text{M}_2$, $-\text{alk-COOR}^{11}$,
20 $-\text{alk-CON}(\text{R}^{11})_2$, and $-\text{O-carbohydrate}$;

R^{11} is independently selected from the group consisting of $-\text{H}$, lower alkyl, cyclic alkyl of 5 to 6 carbon atoms, heterocyclic alkyl of 4 to 5 carbon atoms and 1 to 2 heteroatoms, lower aryl and lower aralkyl;

25 R^{12} is selected from the group consisting of $-\text{N}(\text{R}^{11})_2$, and $-\text{SR}^{11}$;

R^{13} is selected from the group consisting of R^{11} , and M;

R^{14} is selected from the group consisting of -H, and -OR¹⁰, with the proviso that when z is 2, then together the two R^{14} groups may form a double bond;

R^{15} is independently selected from the group
5 consisting of -R¹¹ and -COOH.

M is selected from the group consisting of Na⁺, K⁺, Mg²⁺, and Ca²⁺;

M' is selected from the group consisting of -H, -M, and R⁹; and

10 X is selected from the group consisting of -O-, -S-, -C(R¹¹)₂-, and -N(R¹¹)-; and pharmaceutically acceptable salts thereof with the provisos that:

(a) when any of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are -Y-B and W is a direct link, then at least one adjacent
15 position must be -OH or an ether moiety;

(b) no more than two of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be Y-B when W is a direct link;

(c) no more than three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be a direct link to A;

20 (d) only one of R¹, R⁴, R⁵, and R⁸ may be a direct link to B;

(e) when one of R¹, R⁴, R⁵, or R⁸ is a direct link to B, then at most two of the other naphthyl substituents can be a direct link to A when A is not B;

25 (f) at most three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be independently selected from the group consisting of -OH and ether moieties;

(g) at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is -H;

(h) when any of R^1 , R^4 , R^5 , and R^8 is a direct link to B, then the adjacent position must -OH or an ether moiety;

(i) at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 is a substituent containing a B group, and at least one is a substituent containing an A group where A is not B; and

(j) only when A is directly linked to the naphthyl structure may A be $-(C=O)R^{11}$, and when A is $-(C=O)R^{11}$, at least one adjacent position must be -OH.



The structures that contain the appropriate reactive functions can be reacted with suitably protected hydrophobic carriers like ceramide or a ceramide mimic, steroids, diglycerides or phospholipids to form other medically useful molecules.

The compounds can act as antagonist ligand molecules, i.e. biochemical blocking agents by binding to selectins and preventing circulating leukocytes from binding to endothelial cells, thereby preventing a primary event involved in certain diseases, including cancer, and particularly metastatic cancers, conditions associated with acute inflammation, such as reperfusion injury, septic shock, hypovolemic or traumatic shock, ARDS, and chronic inflammation diseases such as rheumatoid arthritis and asthma. Agonist ligands have the opposite effect.

The compounds of structural formula I can be bound to known drugs, for example anti-inflammatory drugs so as to target the drug-selectin ligand complex to a particular site of disease. Additionally, they can be


formulated to provide compositions useful in assaying a sample for the presence of selectins such as E, L and/or P-selectin, or to detect the site of inflammation in a patient, or to treat acute inflammation (or treating the inflammatory symptoms of certain diseases) or other diseases involving the interaction of selectins on appropriate cell types.

Preferred R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 groups include






20 $-W(CH_2-CR^{11}(OR^{11})CH_2-B)_t$, -OH, lower alkoxy, lower aryloxy, lower araloxy, lower alkoxyaryl, -H, a direct link to A where A is not B, and a direct link to B; where W is a direct link or -O-, and t is 1.

Most preferred are



$-W(CH_2-CR^{11}(OR^{11})CH_2-B)_t$, -OH, -H, and a direct link to A where A is not B.



The preferred examples of A and B are shown respectively in formula V and VI. Other examples of A include α or β or other analogues or derivatives of sialic acid other than the N-acetyl neuraminic acid residue shown in formula V, Kemp's acid, quinic acid, R and S forms of mandelic acid, R and S forms of glyceric acid, R and S forms of lactic acid, propionic and acetic acid, and esters and amides thereof, $-\text{SO}_3$, $-\text{PO}_3$. The synthesis of certain analogues of sialic acid is described in U. S. Patent No. 5,138,044.



VI

Preferred embodiments of the ligands of the invention are those wherein the substituent represented by A or B is an N-acetylneuramyl residue and B is fucose.

Preferred forms of B are the α and β forms of L-fucose as shown in formula VI. The moiety B also includes substituted forms of the following α and β -fucose structure VI:



wherein Me is a methyl group, R^{17} , R^{18} and R^{19} are each independently -OH, -F, $-N(R^9)_2$ (wherein R^9 is lower alkyl). Other moieties for B include modified fucosides such as corresponding carboxylic analogues of fucose;
5 inositol; substituted inositol; imidazole; substituted imidazole; benzimidazole; substituted benzimidazole; Guanidine; pentaerythritol; substituted pentaerythritol; and substituted butanes of the formula
 $-CH_2-CHR^{17}-CHR^{18}-CH_2R^{19}$ wherein R^{12} , R^{18} , and R^{19} are
10 independently -OH, -F or $-N(R^9)_2$.

Preferred B groups include those where s is 1 or 2, R^{14} is -H or -OH, X is -O-, U is $-CH_2OR^{10}$ or $-R^9$, and R^{10} is -alk-COOH, $-SO_3M$, -H, or -alk-COOM. Most preferred are those where s is 2. Particularly preferred B groups
15 include fucose, galactose, mannose, and arabinose.

Preferred s numbers are 1 and 2. Most preferred is 2.

Preferred q numbers are 0 and 1.

Preferred m numbers are 0 and 1.

20 Preferred n numbers are 0 and 3.

Preferred z numbers are 1.

Preferred R^{10} groups are -H, SO_3M , -alk-COOR¹³, and -O-carbohydrate. Most preferred are -H, $-SO_3M$, and -alk-COOR¹³.

25 Preferred R^{11} groups are -H, lower alkyl, and lower aralkyl. Most preferred is -H.

A preferred R^{12} group is $-N(R^{11})_2$.

Preferred R^{14} groups are -H and -OH.

Preferred R^{15} groups are -COOH, -H, and $-CH_3$.

30 A preferred M cation is Na^+ .

Preferred M' groups are -H, Na⁺, and -CH₃.

A preferred X group is -O-.

Preferred U groups are -CH₂OR¹⁰ and -R⁹.

Preferred -W(CH₂(C=C(R¹⁵)₂)-CH₂-B)_t groups are those
 5 where W is a direct link or -O-, t is 1, and R¹⁵ is
 independently -H, -CH₃, and -COOH.

In one preferred aspect, R³ and R⁶ are selected from
 the group consisting of -SO₃M, -OSO₃M, -NO₂, and -CO₂H,
 and at least one of R¹, R², or R⁷ is selected from the
 10 group OH and -NH₂.

In another preferred aspect, R¹ is a direct link to
 B, R² and R³ are selected from the group consisting of
 -OH, -
 -W(CH₂(C=O)CH₂-B)_t, -W(CH₂(C=C(R¹⁵)₂)-CH₂-B)_t,

15
$$\begin{array}{c} \text{OR}_{11} \\ | \\ -\text{W}(\text{CH}_2-\text{C}-\text{CH}_2-\text{B})_t, \text{ and } -\text{W}(\text{CH}_2\text{CH}-\text{CH}_2-\text{B})_t, \text{ and } -\text{W}(\text{CH}_2-\text{CR}^{11}(\text{OR}^{11})\text{CH}_2-\text{B})_t \\ | \qquad \qquad \qquad | \\ \text{C}(\text{R}^{11})_2\text{OR}^{11} \qquad \qquad \text{CH}(\text{R}^{11}), \end{array}$$

20 where W is a direct link and t is 1, R⁷ is -H or
 -OH, and R⁶ is selected from the group consisting of -H
 and -(CH₂)_m-(CHR⁹)_q-(CH₂)_m-A, where each m and q are
 independently selected from 0 or 1, and A is a saturated
 or unsaturated carboxylic acid of 1 to 4 carbon atoms,
 25 optionally substituted with 1 to 2 hydroxy groups, and
 esters and amides thereof. More preferred is where in
 the B group s is 1 or 2, R¹⁴ is -H or -OH, X is -O-, U is
 -CH₂OR¹⁰ or -R⁹, and R¹⁰ is -alk-COOH, -SO₃M, -H, or
 -alk-COOM. Also preferred is where R¹⁵ is -H.

Preferred compounds include those prepared in the Examples and those found in Table 3.

Assaying Compounds of Formula I

The compounds of formula I can be tested for their ability to bind to a selectin receptor and/or block the binding site of the receptor and thereby prevent a natural ligand from binding to the selectin receptor. A generalized procedure for testing the compounds of formula I is given below.

10 An ELISA assay is preferably used that employs recombinant fusion proteins composed of extracellular portions of the human selectins joined to human immunoglobulin heavy chain CH₁, CH₂, and hinge regions. See, for example, Walz et al., Science (1990) 250:1132; 15 Aruffo et al., Cell (1991) 67:35; Aruffo et al., Proc. Natl. Acad. Sci. USA (1992) 89:2292. The assay is well known in the art, and generally consists of the following three steps:

- 20 I. 2,3 sLe^x glycolipid (25 picomole/well) was transferred into microliter wells as solutions and then evaporated off. Excess, which remained unattached, was washed off with water. The wells were then blocked with 5% BSA at room temperature for an hour and then washed with PBS containing 1 mM calcium.
- 25 II. Preparation of "multivalent" receptor of the Selectin-IgG chimera was carried out by combining the respective chimera (1 µg/mL) with biotin labelled goat F(ab'), anti-human IgG (Fc specific) and streptavidin-alkaline phosphatase diluted 1:1000 in 1% BSA-PBS (1 mM

calcium) and incubating at 37°C for 15 min. This allowed the soluble multivalent receptor complex to form.

III. Potential inhibitors such as the compounds of formula I were allowed to react with the soluble receptor at 37°C for 45 min. This test assumes that optimal binding, between the soluble phase receptor complex and the inhibitor (non natural ligand), would have occurred within this time frame. This solution was then placed in the microliter wells that were prepared in step I. The plate was incubated at 37°C for 45 minutes to allow the soluble receptor to bind to its natural ligand. In the presence of a strong inhibitor only a few receptors should be free to bind to the microliter plate coated with the natural ligand.

The positive control is the signal produced by the soluble receptor when it is allowed to react with 2,3 sLe^x glycolipid in the microliter wells in the absence of any inhibitor. This was considered 100% binding. The signal produced by the receptor that had been previously treated with an inhibitor (recorded as O.D.), was divided by the signal produced by the positive control and multiplied by 100 to calculate the % receptor bound to the well in the presence of the inhibitor. The reciprocal of this is the % inhibition.

It is important to note that invention compounds include those having sialic acid and fucose separated by 4-12 atoms, or sialic acid or analogs, derivatives or mimics of sialic acid separated by 4-12 atoms bound to fucose or analogs, derivatives or mimics thereof.

Referring now to Figure 1, a cross-sectional view of a blood vessel 1 is shown. The vessel wall 2 is lined internally with endothelial cells 3. The endothelial cells 3 can be activated causing the cells 3 to synthesize E or P-selectin which is displayed in Figure 1 as a triangular surface receptor 4. Both red blood cells 5 and white blood cells (6A, 6B) flow in the vessel 1. The white blood cells 6 display carbohydrate ligands 7 which have chemical and physical characteristics which allow the ligands 7 to bind to the receptors 4. Once the ligand 7 binds to the receptor 4, the white blood cell 6 is brought through the vessel wall 2 as is shown with the white blood cell 6A. The white blood cells 6B brought into the surrounding tissue 8 can have positive effects, such as fighting infection, and negative effects, such as inflammation.



An important aspect of the present invention can be described by referring to Figure 2. The compounds of formula I are shown as 7A and can adhere to a selectin such as E, L and/or P-selectin by themselves and can be formulated into pharmaceutical compositions, which when administered will effectively block the E, L and/or P-selectin and prevent the adhesion of a ligand 7 connected to a white blood cell 6. By administering pharmaceutically effective amounts of the compounds 7A, some, but not all, of the white blood cells will not reach the surrounding tissue. By slowing the rate at which the white blood cells reach the surrounding tissue, inflammation can be prevented and/or alleviated.

The selectin family of adhesion molecules participate in acute inflammation by initiating neutrophil rolling on activated endothelial cells. This is particularly evident in studies of ischemia
5 reperfusion injury, where P-selectin appears to be important in neutrophil recruitment to damaged tissue. The presence of L-selectin and E- or P-selectin ligands on mononuclear cells has implicated these receptor-ligand interactions in chronic inflammation.
10 This has been supported by the finding of chronic expression of E-selectin in dermatologic conditions, and P-selectin expression on joint synovial endothelium derived from rheumatoid arthritis patients. L. Lasky Annu. Rev. Biochem. 64:113-39 (1995); "Selectin Family
15 of Adhesion Molecules" by Michael Forrest and James C. Paulson in Physiology and Pathophysiology of Leukocyte Adhesion, Ed. by D. Niel Grangier and Deert Schmid-Schönbein, Oxford University Press, N.Y., N.Y. (1995).

The compounds of formula I may also be labeled
20 using standard radioactive, fluorescent, enzymic or other labels for analytical or diagnostic purposes.

In order for a ligand of the invention to bind to a selectin receptor such as E, L and/or P-selectin receptor the ligand need not include the identical atoms
25 in the identical configuration as per structural formula I but must have (1) a relatively stable three dimensional conformation as shown in formula I, or (2) a substantially equivalent configuration to that shown in formula I. The equivalency of any other ligand will
30 relate to its physical three dimensional structure and

the electron configuration of the molecule, and in particular the charge related characteristics presented by the groups present on the A and B moieties shown in formulae V and VI.



5 Assay to Identify Ligand (General)

Candidate ligands can be assayed for their ability to adhere to E, L or P-selectin. The method comprises attaching candidate ligands of formula I to a substrate surface and then contacting the substrate surface thereon with recombinant cells, that are genetically engineered to express high levels of E, L or P-selectin, for a sufficient time to allow the cells to adhere to the substrate bearing the candidate ligand. Thereafter, centrifugal force or other appropriate methodology is applied so as to separate away the cells which do not adhere to the substrate. Candidate ligands which adhere to E, L or P-selectin, respectively, are determined via the labels on the cells. Such molecules are isolated, characterized, and their structure specifically identified.

10

15

20

Radiolabeled COS cells expressing cell surface E, L and/or P-selectin can be used as probes to screen compounds of the invention. E, L or P-selectin transfected COS cells will adhere to a subset of compounds of the invention which can be resolved on TLC plates or adsorbed on PVC microliter wells. Adhesion tests are preferably done under physiological conditions. Adhesion to these compounds may require calcium, but will not be inhibited by heparin, chondroitin sulfate, keratin sulfate, or yeast phospho-mannan (PPME). Monosaccharide composition, linkage analysis, and FAB mass spectrometry of 5 of the purified compounds will indicate that the ligands for E, L or P-selectin share common structural characteristics which generally relate to the moieties A and B and the position in which they are held.

Identification of Compounds Which Act as E, L and/or P-selectin Ligands Using Recombinantly Produced Receptor

A complete cDNA for the E, L and/or P-selectin receptor was obtained by PCR starting with total RNA isolated from IL-1 stimulated human umbilical vein endothelium. The resulting cDNA was inserted into the CDM8 plasmid (see Aruffo et al., Proc. Natl Acad. Sci. USA (1987) 84:8573) and the plasmid amplified in *E. coli*. Plasmid DNA from individual colonies was isolated and used to transfect COS cells. Positive plasmids were selected by their ability to generate COS cells that support HL-60 cell adhesion. DNA sequencing positively identified one of these clones as encoding for E, L

and/or P-selectin (Bevilacqua et al., Science, (1989) 243:1160; Polte et al., Nucleic Acids Res (1990) 18:1083; Hession et al., Proc. Natl. Acad. Sci. USA (1990) 87:1673). These publications are incorporated
5 herein by reference for their disclosure of E-selectin and genetic material coding for its production. The complete nucleotide sequence of the E-selectin cDNA and predicted amino acid sequence of the E-selectin protein are given in the above cited article by Bevilacqua et
10 al., which DNA and amino acid sequences are incorporated herein by reference (see also published PCT patent application W090/13300 which was published November 15, 1990, which is incorporated herein by reference).

COS cells, expressing membrane-bound E, L and/or P-selectin, were metabolically radiolabeled with T_2PO_4
15 (tritiated phosphoric acid). These labeled cells can be used as probes in two assay systems to screen for recognition of the compounds of formula I. More specifically, compounds of formula I may be adsorbed to
20 the bottoms of PVC microliter wells or resolved on TLC plates. In either assay the compounds may be probed for their ability to support adhesion of E, L and/or P-selectin-transfected COS cells, untransfected COS cells, or COS cells transfected with a plasmid containing an
25 irrelevant cDNA, under conditions of controlled detachment force (see Swank-Hill et al., Anal. Biochem. (1987) 183:27; and Blackburn et al., J. Biol. Chem. (1986) 261:2873 each of which is incorporated herein by reference to disclose the details of such assaying
30 methodology).

NSAID or non-steroidal, anti-inflammatory drugs such as naproxen or ibuprofen which act as anti-inflammatory agents could be administered bound to the modified ligand and could be administered.

5 systemically in smaller amounts than usual while obtaining an equivalent effect or even greater anti-inflammatory effect at the site of inflammation. Any other drugs which might be attached include, but are not limited to, antibiotics, vasodilators and

10 analgesics. Such a drug delivery system would reduce any systemic effect normally caused by the drug in that the drugs could be administered in amounts of one-half to one-tenth the normal dose and still obtain the same anti-inflammatory result at the site of inflammation.

15

UTILITY

The invention compounds have considerable utility for the treatment of certain diseases, as set forth herein. However, this is not their only utility. Another utility is identification of particular chemical

20 moieties that are responsible for, or contribute to ligand binding to the different selectins. Using the selectin binding assays described herein it is readily determined which chemical moieties that make up a selectin ligand contribute to selectin binding.

25

It is believed that the compounds of the present invention can be used to treat a wide range of diseases, including diseases such as rheumatoid arthritis and multiple sclerosis. The compositions of the invention should be applicable to treat any disease state wherein

the immune system turns against the body causing the white cells to accumulate in the tissues to the extent that they cause tissue damage, swelling, inflammation and/or pain.

- 5 The inflammation of rheumatoid arthritis, for example, is created when large numbers of white blood cells quickly enter the joints in the area of disease and attack the surrounding tissues.

Formulations of the present invention might also be
10 administered to prevent the undesirable after effects of tissue damage resulting from heart attacks. When a heart attack occurs and the patient has been revived, such as by the application of anticoagulants or thrombolytic (e.g., tPA), the endothelial lining where a
15 clot was formed has often suffered damage. When the antithrombotic has removed the clot, the damaged tissue beneath the clot and other damaged tissue in the endothelial lining which has been deprived of oxygen become activated. The activated endothelial cells then
20 synthesize the E-selectin receptors within hours of the cells being damaged. The receptors are extended into the blood vessels where they adhere to glycolipid ligand molecules on the surface of white blood cells. Large numbers of white blood cells are quickly captured and
25 brought into the tissue surrounding the area of activated endothelial cells, resulting in inflammation, swelling, and necrosis which thereby decreases the likelihood of survival of the patient.

In addition to treating patients suffering from the trauma resulting from heart attack, patients suffering from actual physical trauma could be treated with formulations of the invention in order to relieve the amount of inflammation and swelling which normally result after an area of the body is subjected to severe trauma. Other disease states which might be treatable using formulations of the invention include adult respiratory distress syndrome and various types of arthritis and asthma. After reading the present disclosure, those skilled in the art will recognize other disease states and/or symptoms which might be treated and/or mitigated by the administration of formulations of the present invention.

Radiolabeled compounds of the invention may be prepared in a sterile, non-pyrogenic medium and injected into the bloodstream of a patient at a dose to be determined in the usual way by the physician or radiologist. After a sufficient period for a good balance to have been reached between (i) specificity of binding to activated endothelium compared to non-specific distribution and (ii) total amount of compound on activated endothelium, the compound is imaged in a conventional way, according to the nature of the label used. Use of radiolabelled compounds of the invention could be used to diagnose disease, such as the site of inflammation.


The compounds of the invention could also be used as laboratory probes to test for the presence of a selectin receptor such as a receptor of E, L and/or P-

selectin in a sample. Such probes are preferably labeled such as with a radioactive label. There are a number of known labels including radioactive labeled atoms, e.g. radioactive C, O, N, P, or S, fluorescent
5 dyes and enzyme labels which can be attached to compounds of the invention using known procedures. Labels as well as methods of attaching labels to sugar moieties are disclosed in U.S. Patent No. 4,849,513 issued July 18, 1989 to Smith et al. which patent is
10 incorporated herein by reference to disclose labels and methods of attaching labels.

Method of Synthesis (General)


The compound of formula I can be made using the general and specific synthesis schemes and examples
15 described below. However, those skilled in the art will recognize variations thereof which are intended to be encompassed by the present invention. In general, the A and B moieties of formula I are connected and held in a desired three-dimensional configuration. The compounds
20 of the present invention can be prepared in a number of ways. The following schemes show one preferred method of preparing the compounds of the present invention. Scheme 1 shows the attachment of a B group to the naphthyl structure.

Scheme 1



Scheme 2 shows further elaboration of the naphthyl structure by attachment of another B group through an ether linker. Class I electrophiles are alkyl halide C-glycosides. Class II electrophiles are allylic halide C-glycosides. Class II electrophiles form allylic ethers. "Sugar" refers to C-glycosides below.


Scheme 2



Scheme 3 shows the Claisen Ireland rearrangement of the allylic ether to form a trisubstituted naphthyl structure where the second B group, "sugar₂," is attached through an alkene linker.

5


Scheme 3



Scheme 4 shows several methods of introducing functionality to a sugar. In all three products, the Sugar₁ has been functionalized so that this B group acts as an acid moiety.


5

Scheme 4



Scheme 5 shows another method of introducing acidic functionality onto a sugar.

Scheme 5



Schemes 1-5 also apply to compounds where the naphthyl is replaced by a phenyl or flavanoid structure.

The compound shown above can then be reacted with a fluorescent probe, a multivalent compound, a ceramide, cholesterol or other lipid components, or a pharmaceutically active drug such as an anti-inflammatory drug.


Synthesis of Carbon Glycosides

A vast array of methods for carbon-carbon bond formation at the anomeric carbon are known in the art, which also can be applied to the formation of other heteroatom glycosides, as carbon-phosphorous, carbon-sulfur, carbon-nitrogen, or carbon-silicon bonds at the anomeric position which are understood to be within the invention. The most common method for carbon-carbon bond formation at the anomeric carbon involves nucleophilic attack on this electrophilic center. A wide variety of electrophilic sugars have been employed, such as reducing sugars (or lactols), alkyl glycosides, anomeric esters, glycosyl halides, imidates, anomeric trichloroacetimidates, glycals, lactones, thioglycosides, as well as oxygen-protected glycosides such as acetates and *p*-nitrobenzoates. The carbon nucleophiles that have been used include silyl enol ethers, alkenes, allylsilanes, allylstannanes, cyanides, homoenolates, and organometallics such as Grignard reagents, organolithiums, cuprates, and aluminates. Further, procedures to synthesize carbon-glycosides based on metals (palladium, manganese,

rhodium, and cobalt) have been developed. Concerted reactions such as [4+2] cycloadditions and sigmatropic rearrangements have also been employed to generate carbon glycosides. Also, the Wittig Reaction has
5 extensively been applied to carbon glycoside synthesis, which can be pursued by reaction of hemiacetals followed by ring closure, reaction of sugar lactones, or reaction of anomeric phosphoranes. Other approaches for the synthesis of carbon glycosides encompass, among others,
10 palladium mediated reactions, free radical reactions, and reactions relying on the electrophilic activity of the anomeric center of sugar molecules. Special merits of free-radical methods are mild reaction conditions and tolerance of a wide range of functional groups. The
15 subject of carbon-glycoside synthesis has been reviewed by Hanessian and Pernet, 1976, Adv. Chem. Biochem. 33:111; Postema, 1992, Tetrahedron 48:8545; Postema, C-Glycoside Synthesis, 1995, CRC Press, Ann Arbor, Michigan. Suhadoluid, 1970, Nucleoside Antibiotics
20 Wiley-Interscience: New York; Daves and Cheng, 1976, Prog. Med. Chem. 13:303; Inch, 1984, Tetrahedron 40:3161; Hacksell and Daves, 1985, Prog. Med. Chem. 22:1; and Buchanan, 1983, Prog. Chem. Org Natl. Prod. 44:243; and Levy and Tang, 1995 "The Chemistry of C-
25 glycosides", Pergamon Press.

The following scheme shows the general chemical reaction underlying the generation of activated carbon

glycosides useful for the generation of novel compounds provided by the present invention:



Reagents efficient for the preparation of carbon
 5 glycosides include allyltrimethylsilane (Herscovici and
 Antonakis, 1992, Nat. Prod. Chem. 10:337; Postema,
 1992, Tetrahedron 48:8545; Daves, 1990, Acc. Chem. Res.
 23:201; Hacksell, 1985, Progress in Medicinal Chemistry
 22:1; Hanessian and Pernet, 1976, Adv. Chem. Biochem.
 10 33:111; Carbohydrate Chemistry, Specialist Periodical
 Reports, Royal Chemical Society, 1968-1990, p. 1-24;
 preparation of allyl silanes: Anderson and Fuchs, 1987,
Synthetic Commun. 17:621) and an array of carbon
 nucleophiles available from commercial sources.
 15 Additional examples include, trimethylsilyl enol ethers,
 allyltrimethylsilane, E- and Z-crotyltrialkylsilanes,
 organoaluminum reagents, trialkylstannanes, propargylic
 trialkylstannanes,

[1-(acetoxy)-2-propenyl]trimethylsilane,
[1-(acetoxy)-2-methyl-2-propenyl]-trimethylsilane, and
ethyl-2-propenyltrimethyl-silane-1-carbonate. All are
efficient carbon nucleophiles in the field of carbon
5 glycosidation reactions (Panek and Sparks, 1989, J. Org.
Chem. 54:2034, and references therein). The use of
[1-(acetoxy)-2-methyl-2-propenyl]-trimethylsilane
reagent provides access to terminally oxygen substituted
propenyl groups.

10 Although carbon glycosides can be produced in a few
synthetic transformations, they do not necessarily form
suitable carbon glycosides which could easily be used as
alkylating agents for the preparation of novel
carbohydrate mimics. In one aspect, the present
15 invention provides novel carbohydrate analogues for the
preparation of carbohydrate mimetics. Libraries of
glycomimetics of complex carbohydrates such as, but not
limited, to Sialyl Lewis^x (sLe^x) tetrasaccharide can be
prepared (Rao et al., 1994, The Journal of Biological
20 Chemistry 269:19663; Allanson et al., 1994, Tetrahedron
Asymmetry 5:2061). One of the advantages of having an
allylic halide as an alkylating agent is it would not be
prone to E-2 elimination reactions (see, among other
places, Lowry and Richardson, Mechanisms and Theory in
25 Organic Chemistry, Second edition, 1981, Harper & Row,
New York, p. 530). Among the distinct advantages of
this type of novel carbon glycoside is in the plethora
of new chemical entities created by virtue of the
invention.

For example, several terminally substituted halogen carbon glycosides are efficiently obtained from reaction of 2-chloromethyl-3-trimethylsilyl-1-propene or 2-chloromethyl-3-trimethoxysilyl-1-propene with an activated carbohydrate when the reaction is catalyzed by Lewis acid. Thereby, the allylsilanes can undergo a stereochemically controlled axial addition to the pyranose oxonium ions produced by Lewis acid catalysis and anomeric acetates. Benzyl protected carbohydrates result in a stereoselective and efficient route to A-C-glycosides, incorporating an allylic chloride. The use of the per-O-acetylated carbohydrates offers added versatility by avoiding the hydrogenolysis step required for O-benzyl protected sugars. Nashed and Anderson, 1982, J. Amer. Chem. Soc. 104:7282; Panek and Sparks, 1989, J. Org. Chem. 54:2034.

2-Chloromethyl-3-trimethylsilyl-1-propene and 2-chloromethyl-3-trimethoxysilyl-1-propene reagents react with benzyl protected carbohydrates with equal efficiency while per-O-acetylated carbohydrates show better results with the 2-chloromethyl-3-trimethylsilyl-1-propene reagent. Examples for the carbon glycoside synthesis as employed by the subject invention are provided by the instant disclosure, *infra*. Both the α - and the β - configuration are part of the invention.

Methods for the Generation of Novel Compounds Comprising Carbon Glycosides

The tools and methods of the present invention are focused towards the incorporation of carbohydrates into existing and novel organic compounds, and combinatorial chemical libraries.

The carbohydrate moieties employed for the generation of such naphthyl compounds and libraries include monomers, dimers, trimers, oligomers, branched or unbranched, linked to a suitable functional group of a chemical moiety comprising such functional group. Suitable functional groups include, but are not limited to, phenolic, hydroxyl, carboxyl, thiol, amido, and amino groups. In the case a moiety has more than one such suitable functional group, one or more such functional groups may be protected by suitable protecting groups during the coupling reaction. Such protecting groups include lower methyl-, benzyl-, benzoyl-, acetyl-, MOM, MEM, MPM, tBDMS, or TMS groups. After the coupling reaction, the protecting groups may selectively be removed.

In all cases, every molecule comprising at least one suitable functional group can be employed as substrate to react with the activated carbon glycosides/heteroatom glycosides of the present invention.

Protecting Groups

The monomers of the present invention, i.e., the carbohydrates used for the formation of carbon glycosides, the carbon glycosides, and/or the substrates may have groups protecting part of the functional groups within the monomer. Suitable protecting groups will depend on the functionality and particular chemistry used to generate the novel compound or combinatorial chemical library. Examples for suitable functional protecting groups will be readily apparent to those of ordinary skill in the art, and can be found, among other places, in Greene and Wutz, 1991, Protecting Groups in Organic Synthesis, 2d ed., John Wiley & Sons, NY. Protecting groups typically used when modifying the anomeric position of carbohydrates are apparent to one of ordinary skill in the art. In addition, a plurality of functional groups may be employed. The C-atom of the carbohydrate used for the formation of the carbon glycosidic bond can be modified by differential protection of functional groups, as it will be apparent to those of ordinary skill in the art. Most preferred protecting groups of the present invention comprise benzyl- and acetyl-groups.

Coupling Reactions

Carbon glycoside reagent can be functionalized to be used in a plethora of chemical reactions in order to form unique compounds. Suitable functionalized carbon glycosides can be attached, for example, to phenolic, hydroxyl, carboxyl, thiol, amino, amido, and/or


equivalent functionality under mild conditions.
Activated forms of C-glycosides are alkylhalide, alkenyl
halide, or some equivalent activated form. The coupling
reactions for activated C-glycosides can be performed to
5 form novel compounds under standard conditions typically
used for alkyl and alkenyl chlorides, bromides, iodides,
acetates, alcohols, Grignards, etc. In addition, the
alkenyl C-glycosides offer routes into Cope
rearrangements, Claisen rearrangements, and allylic
10 couplings, as they are readily known by those of
ordinary skill in the art and as are described in
various examples provided hereinbelow to form novel
glycomimetics and unique compounds.

Many named standard reaction conditions using
15 allylic halides parallel the use of carbon glycosides
containing allylic halide functionality to prepare novel
compounds and functional groups, including but not
limited to the Alper Reaction, Barbier Reaction,
Claisen-Ireland Reaction, Cope Rearrangement, Delepine
20 Amine synthesis, Gewald Heterocycle Synthesis,
Hiyama-Heathcock Stereoselective Allylation, Stork
Radical Cyclization, Trost Cyclopentanation, Weidenhagen
Imidazole Synthesis. See, in general, Hassner and
Stumer, 1994, "Organic Syntheses Based on Named
25 Reactions and Unnamed Reactions", Tetrahedron Organic
Chemistry Series, eds. Baldwin and Magnus, Pergamon,
Great Britain.

One of ordinary skill in the art will appreciate that the methods of the present invention can be used to incorporate carbohydrate units or analogues thereof in virtually any naphthyl based structure. In the case
 5 where a substrate Naphthyl structure comprises more than one suitable functional group to react with the functionalized C-glycosides of the present invention, these functionalities need not be identical.

Interconversion of Alkenyl Linkers

10 The alkenyl C-Glycoside compounds described and utilized here are of particular utility due to the reactivity of the activated alkenyl C-glycoside reagent, and the diverse array of transformations and functional group modifications possible around the alkenyl moiety.
 15 The scheme below illustrates some of the more common transformations that can be applied to these structures, with the understanding that many additional modifications are possible to one of ordinary skill in the art.



SUBSTITUTE SHEET (RULE 26)

As illustrated in the above scheme, the alkenyl moiety is easily converted to the saturated substituted alkyl form using standard catalytic hydrogenation conditions as found in advanced organic chemistry reference textbooks. Treatment of the alkene with 9-BBN followed by treatment with basic hydrogen peroxide, or equivalent conditions, provided the primary alcohol derivative. Oxidation of the alcohol using known conditions would provide the carboxylic acid analog.

10 The vicinal diol derivative can be prepared by oxidation with osmium tetra oxide and NMO or similar bishydroxylation conditions as described in standard texts on organic chemistry. The ketone derivative can be made from diol by oxidative cleavage reaction

15 conditions including periodate oxidation. Alternately, the ketone can be prepared by direct treatment of the alkene with osmium tetroxide and periodate. The ketone can then provide the secondary alcohol by reduction with reducing agents such as sodium borohydride.

20 The diol group described above is suited to a variety of O-alkylation and O-acylation reactions, with O-sulfation being a particularly useful method for introducing anionic functionality into the linker. The ketone can undergo subsequent modifications via wittig

25 reactions as described to yield the substituted alkene groups, or following reduction by catalytic hydrogenation, yielding substituted alkyl linker groups.

The common transformations described above are generally known to one skilled in the art and the

30 methodologies described, and equivalent methodologies

are available in advanced organic chemistry textbooks, and references cited therein. For some general references to these chemistries please see the appropriate Example.

5 Claisen-Ireland Rearrangement: General Example.


The rearrangement of allyl aromatic ethers to ortho or para allylaromatic alcohols, or the rearrangement to adjacent positions relative to the alkylated phenol moiety, can be accomplished in a two step format. The
10 first step is to alkylate the phenol, which can be done using the procedure herein disclosed or by using the optional procedure used in the following example using sodium methoxide. The result is the o-alkylated naphthols.

15 The alkylated naphthols can then be refluxed in the appropriate solvent such as dimethylaniline or 1,2-dichlorobenzene for 3-12 hours (depending on the substrate) to give the Claisen-Ireland product.

Claisen-Ireland Rearrangement: 2-Naphthol Example.

20 The rearrangement of allyl naphthol ethers to ortho or para allylphenols can be accomplished in a two step

format. The first step is to alkylate the phenol, which can be done using the procedures herein disclosed.




The allylic naphthol is refluxed in dimethylaniline
5 or dichlorobenzene for 3-12 hours to give the 1-(allyl-
2,3,4-tri-O-benzyl-alpha-C-Fucoside)-2-naphthol.

Aromatic Nucleophiles: The O-C Migration.

The O to C rearrangement of O-phenyl glycosides has
been reported to generate aromatic C-glycosides (M.H.D.
10 Postema, C-Glycoside Synthesis, CRC Press, page 2-42,
c1995, CRC Press, Inc., ISBN 0-8493-9150-4, Ann Arbor,
Michigan, and references therein). Kometani and
collaborators (T. Kometani, H. Kondo, Y. Fumimori,
Synthesis, 1005, (1988)) have used the O to C migration
15 for the preparation of aromatic C-glycosides. Its use
in the preparation of sLex mimics and its use in
conjunction with the Claisen-Ireland rearrangement
contained in this application is new. When these
compounds are exposed to a Lewis acid, the rearrangement
20 takes place to give the beta-aryl-C-glycoside.

Typically, beta isomer is the major component. In these reactions, the regioselectivity of 2-naphthols gives the C-glycoside at the 1-position while the 1-naphthols give the C-glycoside at the 2-position. Using this methodology in conjunction with the Claisen-Ireland type of rearrangements gives novel compounds of the invention.

Example (Kometani, et al):



Use and Administration

The compounds of the invention such as various ligands of structural formula I can be administered to a subject in need thereof to treat the subject by either prophylactically preventing inflammation or relieving it after it has begun. The ligands are preferably administered with a pharmaceutically acceptable carrier, the nature of the carrier differing with the mode of administration, for example, oral administration, usually using a solid carrier and I.V. administration a liquid salt solution carrier. The formulation of choice can be accomplished using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders. Particularly useful is the administration of the compounds directly in transdermal formulations with permeation enhancers such as DMSO. Other topical formulations can be administered to treat dermal inflammation.

A sufficient amount of compound(s) would be administered to bind to a substantial portion of the selectin expected to cause or actually causing the disease, for example, inflammation so that inflammation can either be prevented or ameliorated. Thus, "treating" as used herein shall mean preventing or ameliorating the appropriate disease. Typically, the compositions of the instant invention will contain from less than 1% to

about 95% of the active ingredient, preferably about 10% to about 50%. Preferably, between about 10 mg and 50 mg will be administered to a child and between about 50 mg and 1000 mg will be administered to an adult. The
5 frequency of administration will be determined by the care given based on patient responsiveness.

Other effective dosages can be readily determined by one of ordinary skill in the art through routine trials establishing dose response curves.

10 When determining the dose of compounds to be administered which block selectin receptors, it must be kept in mind that one may not wish to completely block all of the receptors. In order for a normal healing process to proceed, at least some of the white blood
15 cells or neutrophils must be brought into the tissue in the areas where the wound, infection or disease state is occurring. The amount of the ligands administered as blocking agents must be adjusted carefully based on the particular needs of the patient while taking into
20 consideration a variety of factors such as the type of disease that is being treated.

Other modes of administration will also find use with the subject invention. For instance, the ligand molecules of the invention can be formulated in
25 suppositories and, in some cases, aerosol and intranasal compositions. For suppositories, the vehicle composition will include traditional binders and carriers such as, polyalkylene glycols, or triglycerides. Such suppositories may be formed from mixtures
30 containing the active ingredient in the range of about

0.5% to about 10% (w/w), preferably about 1% to about 2%.

Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function. Diluents such as water, aqueous saline or other known substances can be employed with the subject invention. The nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.

The compounds of the instant invention may also be administered as injectables. Typically, injectable compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.

Compounds of formula I can be mixed with compatible, pharmaceutically acceptable excipients. Suitable vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those of ordinary skill in the art. See, e.g. Remington's

Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pennsylvania, 17th edition, 1985. The
composition or formulation to be administered will, in
any event, contain a quantity of the compounds adequate
5 to achieve the desired state in the subject being
treated.

The various compounds of the present invention can
be used by themselves or in combination with
pharmaceutically acceptable excipient materials as
10 described above. However, the compounds of the
invention can be made as conjugates wherein they are
linked in some manner (e.g., via the R¹ moiety) to a
label. By forming such conjugates, the compounds can
act as biochemical delivery systems for the label so
15 that a site of disease can be detected.

For instance, carbohydrates can be labelled by a
variety of procedures, for example: esterification of
hydroxyl bonds to form a structure capable of complexing
directly with a radioisotope or NMR enhancer; reaction
20 of the carbohydrate with amino diacetic acid (IDA) in
organic solvent to form an N-linked glycoside derivative
which would be capable of complexing with a radioisotope
via the nitrogen and oxygen atoms of the IDA group; or
coupling of the carbohydrate to amino acids which may be
25 labelled directly (e.g. cysteine, tyrosine) or labelled
via a bifunctional chelating agent (e.g., lysine).

Appropriate radioactive atoms would include, for
example, technetium 99m (^{99m}Tc), iodine-123 (¹²³I) or
indium-111 (¹¹¹In) for scintigraphic studies, or for
30 nuclear magnetic resonance (NMR) imaging (also known as

magnetic resonance imaging, MRI), a label such as gadolinium, manganese or iron, or a positron-emitting isotope such as iodine-124, fluorine-19, carbon-13, nitrogen-15 or oxygen-17.

5

EXAMPLES

The compounds of this invention and their preparation can be understood further by the following examples which illustrate some of the processes by which these compounds are prepared. The following examples
10 are provided so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make compounds and compositions of the invention and are not intended to limit the scope of what the inventors regard as their invention. The compounds of
15 the present invention can be prepared by methods now known or later developed. Unless indicated otherwise, parts are parts by weight, temperature is in degrees C, and pressure is at or near atmospheric. .

Materials and Methods

20 Reagents were purchased from commercial suppliers such as Pfanstiehl Laboratories, Aldrich Chemical Company or Lancaster Synthesis Ltd. and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF) and dimethylformamide (DMF) were
25 purchased from Aldrich in sure seal bottles and used as received. All solvents were purified by using standard methods readily known to those of ordinary skill in the art unless otherwise indicated.

General Protocol

The reactions set forth below are done generally under a positive pressure of nitrogen or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried. Analytical thin layer chromatography (TLC) was performed on glass-backed silica gel 60 F 254 plates Analtech (0.25 mm) and eluted with the appropriate solvent ratios (v/v) which are noted where appropriate. The reactions were assayed by TLC and terminated as judged by the consumption of starting material.

Visualization of the TLC plates were done with a *p*-anisaldehyde spray reagent or phosphomolybdic acid reagent (Aldrich Chemical 20% wt in ethanol) and activated with heat. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume unless otherwise indicated. Product solutions were dried over anhydrous Na₂SO₄ prior to filtration and evaporation of the solvents under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo.

Flash column chromatography (Still et al., 1978, A.J. Org. Chem. 43:2923) was done using Baker grade

flash silica gel (47-61mm) and a silica gel: crude material ratio of about 20:1 to 50:1 unless otherwise stated.

Hydrogenolysis can be done at the pressure indicated in the examples, or at ambient pressure.

¹H-NMR spectra were recorded on a Varian 300 instrument operating at 300 MHz and ¹³C-NMR spectra were recorded on a Varian 300 instrument operating at 75 MHz. NMR spectra were obtained as CDCl₃ solutions (reported in 10 ppm), using chloroform as the reference standard (7.25 ppm and 77.00 ppm) or CD₃OD (3.4 and 4.8 ppm and 49.3 ppm) or internally tetramethylsilane (0.00 ppm) when appropriate. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d 15 (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz.

Infrared spectra were recorded on a Perkin-Elmer FT-IR Spectrometer as neat oils, or a CDCl₃ solutions, 20 and are reported in wave numbers (cm⁻¹).

The mass spectra were obtained using LSIMS. All melting points are uncorrected. Microanalyses were carried out by Galbraith Laboratories, Inc., Knoxville, TN.

Catalytic ReductionCatalytic Hydrogenation for the Reduction of an Alkene or Removal of the Benzyl Group.

For a compound containing an alkene, 1.00 mmole
5 equivalent is dissolved in an appropriate hydrogenation
solvent suitable for the compound to be deprotected.
Solvents can include but not restricted to, methanol,
ethyl acetate, ethanol, acetic acid or combinations
thereof. For example, methanol with a catalytic amount
10 of acetic acid or ethyl acetate and methanol can be used
as the hydrogenation solvent. 5% or 10% palladium on
carbon (1 g for every 50 grams of starting material with
the catalyst wetted with toluene under argon) is
evacuated and hydrogen gas is added and the process
15 repeated three times. The reaction is shaken or stirred
for several hours until the deprotection is complete.
The reaction can be done under ambient pressures or can
be done a hydrogenation bomb at appropriate pressures
(generally 10-50 psig). The reaction is terminated by
20 removal of the excess hydrogen gas, flushing the
reaction vessel with an inert atmosphere and then
filtering the contents through Celite to remove the
catalyst and washing the catalyst with 30% methanol in
chloroform or appropriate solvent system. Concentration
25 in vacuo afforded the desired compound. The product can
be purified by column chromatography using Baker grade
fresh silica gel (47-61mm) and a suitable solvent
system. For example, 10% ethyl acetate in hexanes and
then with 30% ethyl acetate in hexanes. The silica gel
30 is eluted with methanol and checked by TLC for any

product material. The solvents are removed in vacuo and the product dried under vacuum. The desired product is recovered.

General references on applicable transformations
5 can be found, among other places, in:

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East 23rd Street, Suite 909, New York, NY 10010.

Jerry March, Advanced Organic Chemistry, 3rd
10 Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York USA.

H. O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

15 F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

20 **9-BBN**

For a compound containing an alkene, (1.00 mmole equiv.) is dissolved in an appropriate solvent suitable for the compound to be reduced with 9-BBN (9-borabicyclo[3.3.1]nonane) or equivalent. Solvents can
25 include but not restricted to, tetrahydrofuran (THF), hexanes and diethyl ether, or combinations thereof. To a stirred solution of the olefin, (1.00 mmole equiv.) in THF (0.5M) at 0°C is added 9-BBN pre-dissolved in THF (1.00 mmole equiv.) is carefully added. The reaction

contents are stirred at 0°C and the cooling bath (water/ice) is allowed to melt the reaction allowed to stir at ambient temperature for 8 hours or until the reaction is complete via analysis by TLC. The reaction
5 is terminated by the careful addition acetone and stirred for 1 hour at room temperature. The reaction contents are cooled to 0°C and then 1.0 M NaOH and 30% H2O2 are added to decompose the alkyl borate. The contents are stirred until the alkyl borate decomposes
10 to the carbonol. An extraction solvent such as chloroform or ethyl acetate is added and the heterogeneous layers are separated and the organic phase is washed with 1.0M hydrochloric acid, water and brine. The washed product is dried over anhydrous sodium
15 sulfate and filtered. The product can be purified by column chromatography using Baker grade flash silica gel (47-61mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate in hexanes or appropriate solvent mixtures
20 dependant upon the particular substrate used. The silica gel is eluted with methanol and checked by TLC for any product material. The solvents are removed in vacuo and the product dried under vacuum the desired product is recovered.

25 General references on applicable transformations can be found, among other places, in:

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East 23rd Street, Suite 909, New York, NY 10010.

Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York USA.

H. O. House, Modern Synthetic Reactions, c1972,
5 ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing
10 Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

Oxidation

General references on applicable transformations can be found, among other places in:

15 M. Hudlicky, Oxidations in Organic Chemistry, ACS Monograph #186, c1990, ISBN 0-8412-1781-5, Published by The American Chemical Society, Washington, D.C.

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East
20 23rd Street, Suite 909, New York, NY 10010.

Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York USA.

H. O. House, Modern Synthetic Reactions, c1972,
25 ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing

Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

Bis-Hydroxylation

Bishydroxylation of the olefin via Oxidation with
5 osmium tetroxide. To a stirred solution of the olefin,
(1.00 mmole equiv.) in 1% water in acetone (0.5M) at 0°C
is added osmium tetroxide pre-dissolved in acetone (0.01
mmole equiv.) and N-methylmorpholine-N-oxide (2.00 mmole
equiv.) is carefully added as a solid. The reaction
10 contents are stirred at 0°C and the cooling bath
(water/ice) is allowed to melt the reaction allowed to
stir at ambient temperature for 18 hours or until the
reaction is complete via analysis by TLC. The reaction
can be assayed by TLC or an aliquot of the reaction
15 acetate. The aliquot is checked by ¹H-NMR in CDCl₃. The
reaction is terminated by the careful addition sodium
bisulfite (contains a mixture of NaHSO₃ and Na₂S₂O₅),
stirred for 1 hour at room temperature and then water.
An extraction solvent such as chloroform is added and
20 the heterogeneous layers are separated and the organic
phase is washed with 1.0M hydrochloric acid, water and
brine. The washed product is dried over anhydrous
sodium sulfate and filtered. The product can be
purified by column chromatography using Baker grade
25 flash silica gel (47-61mm) and a suitable solvent
system. For example, 10% ethyl acetate in hexanes and
then with 30% ethyl acetate in hexanes. The silica gel
is eluted with methanol and checked by TLC for
product material. The solvents are removed in vacuo and

the product dried under vacuum the desired product is recovered.

General references on applicable transformations can be found, among other places, in:

- 5 R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East 23rd Street, Suite 909, New York, NY 10010.

- Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons
10 Publishers, New York USA.

H. O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

- F.A. Carey and R.J. Sundberg, Advanced Organic
15 Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

Sulfation

- 20 Sulfation of hydroxyl functionalities. In a preferred embodiment, the hydroxy groups of the target molecule are sulfated under standard conditions: For example, to a solution of 0.35 g 3,4-di-C-fucosyl caffeic acid (0.603 mmole, 1 mmole equiv.) in 7.2 mL pyridine was
25 added 1.15 g sulfur trioxide pyridine complex (7.24 mmole, 12 mmole equiv.) and the reaction was stirred at ambient temperature for 12 hours. The reaction was complete as assayed by TLC at CHCl₃:MeOH:H₂O 10:10:1 (v/v) as assay conditions. To the mixture was added

methanol and the solution was stirred for 1 hour. All of the solvents were evaporated and the residue was chromatographed on Bakerbond Octadecyl (40 μ m) silica gel and eluted with water and 10% methanol in water. To the
5 combined fractions was subjected to sodium ion exchange resin for the exchange of residual ionic salts for sodium ions. Lyophilization provided persulfated 3,4-di-C-fucosyl sodium cafeate.

As an additional alternative method: To a solution
10 of the alcohol(s) groups to be sulfated from the products of the invention (1.00 mmole equiv.) in anhydrous pyridine or diemthylformamide (0.2M) at ambient-temperature was added sulfur trioxide pyridine complex of the sulfur trioxide pyridine complex polymer
15 bound [Graf, W. chem. Ind. 1987, 232.] (10 mmole equiv.). The reaction contents were stirred at ambient temperature for 8 hours. The reaction was quenched using sodium carbonate and removing the solvents by lyophilization and the resulting material was subjected
20 to sodium ion exchange resin for the exchange of residual ionic salts for sodium ions. Concentration in vacuo affords the sulfated materials.

The experimental procedures described can be applied to make and modify the following exemplified
25 novel products.

General references on applicable transformations can be found, among other places, in:

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East
30 23rd Street, Suite 909, New York, NY 10010.

G.A. Olah, et al, Synthesis, 59, (1979), G.A. Olah, et al, Synthesis, 984, (1979), Y. Hamada, T. Shiori, Chem. Pharm. Bull. 30, 1921, (1982).

Ketone Formation

- 5 Oxidation of the alkene to the ketone via catalytic oxidation with osmium tetroxide sodium periodate. To a stirred solution of the olefin, (1.00 mmole equiv.) in 1% water in acetone (0.5M) at 0°C is added osmium tetroxide pre-dissolved in acetone (0.01 mmole equiv.)
- 10 and sodium periodate (2.00 mmole equiv.) is carefully added as a solid. The reaction contents are stirred at 0°C and the cooling bath (water/ice) is allowed to melt and the reaction allowed to stir at ambient temperature for 18 hours or until the reaction is complete via
- 15 analysis by TLC. The reaction can be assayed by TLC or an aliquot of the reaction contents is removed, quenched into aqueous sodium metasilfite and extracted with ethyl acetate. The aliquot is checked by ¹H-NMR. The reaction is terminated by the careful addition sodium bisulfite
- 20 (contains a mixture of NaHSO₃ and Na₂S₂O₅), stirred for 1 hour at room temperature and then water. An extraction solvent such as chloroform is added and the hydrochloric acid, water and brine. The washed product is dried over anhydrous sodium sulfate and filtered. The product can
- 25 be purified by column chromatography using Baker grade flash silica gel (47-61mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate in hexanes. The silica gel is eluted with methanol and checked by TLC for any

product material. The solvents are removed in vacuo and the product dried under vacuum. The desired product is recovered.

General references on applicable transformations
5 can be found, among other places, in:

M. Hudlicky, Oxidations in Organic Chemistry, ACS Monograph #186, c1990, ISBN 0-8412-1781-5, Published by The American Chemical Society, Washington, D.C.

R. Pappo, D.S. Allen Jr., R.U. Lemieux, W.S.
10 Johnson, J. Org. Chem., 21, 478, (1956).

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc. 220 East 23rd Street, Suite 909, New York, NY 10010.

Jerry March, Advanced Organic Chemistry, 3rd
15 Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York USA.

H. O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

20 F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

25 Wittig (Ester)

The use of a Wittig reagent for the conversion of a ketone to an alpha, beta unsaturated ester can be found in the additional references:

R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc., 220 East 23rd Street, Suite 909, New York, N.Y. 10010

Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York, USA.

H.O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

10 F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

15 Wittig (Alkene)

The use of a radiolabelled Wittig reagent for the conversion of a ketone to an alkene can be found in Bioorg. Chem. 19, 327, (1991) or J. Amer. Chem Soc. 111, 3740, (1989). Additional references can be found on applicable transformations in:

20 R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc., 220 East 23rd Street, Suite 909, New York, N.Y. 10010.

Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York, USA.

H.O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, Menlo Park, California, USA.

F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, USA.

Sodium Borohydride Reduction

For a compound containing a ketone, (1.00 mmole equiv.) is dissolved in an appropriate solvent suitable for the compound to be reduced with sodium borohydride or equivalent. Solvents can include but not restricted to, tetrahydrofuran (THF), hexanes and diethyl ether, or combinations thereof. To a stirred solution of the ketone, (1.00 mmole equiv.) in THF (0.5M) at 0°C is added sodium borohydride pre-dissolved/suspended in THF (1.00 mmole equiv.) is carefully added. The reaction contents are stirred at 0°C and the cooling bath (water/ice) is allowed to melt the reaction allowed to stir at ambient temperature for 8 hours or until the reaction is complete via analysis by tlc. The reaction is terminated by the careful addition acetone and stirred for 1 hour at room temperature. Water is carefully added and the reaction contents stirred to decompose the alkyl borate. The contents are stirred until the alkyl borate decomposes to the carbonol. An extraction solvent such as chloroform or ethyl acetate is added and the heterogeneous layers are separated and the organic phase is washed with 1.0M hydrochloric acid, water and brine. The washed product is dried over anhydrous sodium sulfate and filtered. The product can

be purified by column chromatography using Baker grade flash silica gel (47-61mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate in hexanes or appropriate solvent mixtures dependent upon the particular substrate used. The silica gel is eluted with methanol and checked by TLC for any product material. The solvents are removed in vacuo and the product dried under vacuum the desired product is recovered.

10 General references on applicable transformations can be found, among other places, in:

 R.C. Larock, Comprehensive Organic Transformations, ISBN 0-89573-710-8, 1989, VCH Publishers, Inc., 220 East 23rd Street, Suite 909, New York, N.Y. 10010.


15 Jerry March, Advanced Organic Chemistry, 3rd Edition, c1985, ISBN 0-471-88841-9, John Wiley & Sons Publishers, New York, USA.

 H.O. House, Modern Synthetic Reactions, c1972, ISBN 0-8053-4501-9, The Benjamin/Cummings Publishing Company, 20 Menlo Park, California, USA.

 F.A. Carey and R.J. Sundberg, Advanced Organic Chemistry Parts A & B, 2nd Edition, c1983, ISBN 0-306-41199-7, Plenum Press, a division of Plenum Publishing Corporation, 233 Spring Street, New York, N.Y. 10013, 25 USA.

Example 1Generation of Compounds: General ReactionGeneral Experimental Procedures:

One of ordinary skill in the art will appreciate
5 and understand the following general experimentals as
they are used in the art to prepare novel compounds from
the invention. The mmole equivalents refers to the
reaction substrate to be functionalized by the reaction
with the carbon glycoside reagent per position to be
10 alkylated. Additional functional group transformations
can be accomplished by the skilled artisan using
standard reaction conditions. For example, the
transofmration of allylic halides into allylic amines
can be via the allylic azide with reduction of the azide
15 to the amine with triphenylphosphine in water. The
amine is then available for amide bond formation.




Alkylation conditions using Sodium hydride and an Aliphatic Alcohol. To a mechanically stirred solution of sodium hydride (3.00 mmole equiv. Note: the sodium hydride is washed three times with hexanes prior to use.) in THF (slurry) at ambient temperature is added an
5 aliphatic alcohol (1.00 mmole equiv.) dropwise in a minimum of anhydrous tetrahydrofuran. Tetrabutylammonium iodide (0.10 mmole equiv.) is added and the reaction contents are stirred at room
10 temperature (slight warming to above room temperature is sometimes needed for the initiation of the reaction) for 60 minutes in order to minimize the rate of gas evolution. The reaction contents are warmed to for a period of 2 hours; carefully watching for the evolution
15 of hydrogen. The reaction contents are stirred using a mechanical stirrer while being gently refluxed for a period of 1.5 hours. A benzyl protected carbon
gylcoside reagent to be used (1.50 mmole equiv.) is slowly added dropwise in anhydrous tetrahydrofuran
20 (total reaction concentration of 0.2 to 0.5 M) over a period of 1-2 hours and stirred for 4 hours. [An aliquot of the reaction contents is removed and quenched into 1.0M HCl and extracted with ethyl acetate; the TLC
conditions used are 5% methanol in chloroform (v/v.) The
25 reaction is then diluted with toluene and terminated by the careful addition of 50% methanol in toluene at 0°C to consume the residual sodium hydride, followed by
acidification of 1.0M hydrochloric acid until the pH is about 2. The reaction contents are diluted with ethyl
30 acetate. The heterogeneous layers are separated and the

organic phase is washed twice with portions of 1.0M hydrochloric acid, saturated sodium thiosulfate and brine. The product can be purified by column chromatography using Baker grade flash silica gel (47-61 mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate in hexanes. The silica gel is eluted with methanol and checked by TLC for any product material. The solvents are removed in vacuo and the product dried under vacuum. The desired product is recovered.

General alkylation conditions using Cesium Carbonate as a mild base for the alkylation of thiols, amines, carboxylic acids and the like. To a stirred solution of thiols, phenols, amines, carboxylic acids and the like (1.00 mmole equiv.) in DMF or acetone (0.5M) is added cesium carbonate (3.00 mmole equiv.) and the Carbon-glycoside reagent (1.50 mmole equiv.). The reaction is stirred at room temperature for 12 hours. The reaction is assayed by TLC. The TLC conditions are usually 30% ethyl acetate in hexanes (v/v). The reaction contents are diluted with ethyl acetate and then poured into cold water. The organic layer is washed twice with water and then brine. The product is dried over anhydrous sodium sulfate and filtered to remove the drying agent. The solvent is removed in vacuo. The product can be purified by column chromatography using Baker grade flash silica gel (47-61mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate

in hexanes. The silica gel is eluted with methanol and checked by TLC for any product material. The solvents are removed in vacuo and the product dried under vacuum. The desired product is recovered.

- 5 **Removal of the acetyl protecting groups from the acetylated carbon glycosides.** To a solution of the acetyl protected compounds (1.00 mmole equiv.) in methanol (0.5M) is added cesium carbonate or sodium methoxide (5.00 mmole equiv.) and water (catalytic) and
- 10 the contents stirred for 48 hours. The reaction is quenched with 1.0M HCl until the pH is approximately 1. The product is extracted with an appropriate extraction solvent such as chloroform and the organic layer is washed with water. The product is dried over anhydrous
- 15 sodium sulfate and filtered to remove the drying agent. The product can be purified by column chromatography using Baker grade flash silica gel (47-61mm) and a suitable solvent system. For example, 10% ethyl acetate in hexanes and then with 30% ethyl acetate in hexanes.
- 20 The silica gel is eluted with methanol and checked by TLC for any product material. The solvents are removed in vacuo and the product dried under vacuum. The desired product is recovered.

Example 2Preparation of 1-Deoxy-1- α -Iodoethyl-2,3,4-Tri-O-Acetyl-L-Fucose (2)

A solution of tetraacetylated L-fucose (9.0 g, 27.1
 5 mmole) in acetonitrile (100 mmole) was stirred with one
 teaspoon of powdered molecular sieves (4Å) for 30
 minutes. This was mixed with allyltrimethylsilane (17.6
 ml) followed by boron-trifluoride etherate (17.6 ml)
 solution in one portion. This reaction mixture was
 10 stirred at room temperature for three days. Most of
 volatiles were removed in vacuo and diluted with a 1:1
 mixture of saturated sodium bicarbonate and brine
 solutions (100 ml). This was extracted with ethyl
 acetate (2 x 200 ml) and the combined organic extracts
 15 were washed with saturated sodium bicarbonate and brine
 solutions, dried over sodium sulfate, filtered and
 concentrated. The crude was purified on a silica gel
 column (hexane: ethyl acetate, 3:1) to provide
 allylfucose 7.97 g, 94%).

20 A solution of allylfucose (5.1 g, 16.3 mmole) in a
 mixture of dichloromethane (80 ml) and methanol (20 ml)
 at -78°C was bubbled with ozone until the blue color
 persisted. Excess ozone was removed by passing oxygen
 through the solution. This was mixed with

dimethylsulfide (10 ml) and stirred at -78°C to room temperature overnight. All the volatiles were removed in vacuo and dissolved in methanol (50 ml). At -78°C, this was mixed with sodium borohydride (620 mg) and
5 warmed up to 0°C and stirred for one hour. This is poured into water (50 ml) and extracted with ethyl acetate (2 x 100 ml). The organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude product was purified on a
10 silica gel column (hexane: ethyl acetate, 1:1) to provide the alcohol (1.95 g, 38% yield). A much higher yield (90%) of the alcohol is obtained if sodium triacetoxymethylborohydride is used instead of sodium borohydride.

15 A solution of the above alcohol in pyridine (10 ml) and p-toluenesulfonylchloride (1.75 g) was stirred at 0°C for 14 hours. This mixture was quenched with water (20 ml) and stirred for 20 minutes. This mixture was acidified with 6N of hydrochloride solution and
20 extracted with ethyl acetate (2 x 100 ml). The combined organic extracts were then washed with water (100 ml), saturated sodium bicarbonate (30 ml), brine (30 ml), dried over sodium sulfate, filtered and concentrated to provide the crude tosylate. This crude product was
25 heated with sodium iodide (3 g) in acetone (40 ml) at 450°C for 2 hours. After cooling, the mixture was evaporated and the residue worked up with water (50 ml) and ethyl acetate (200 ml). The crude mixture was purified on a silica gel column (hexane ethyl acetate,
30 2:1) to provide the iodide 2 (2.9 g, 76%).

Example 3Synthesis of "Activated" Carbon Glycoside Building Blocks

A preferred method for the synthesis of terminally substituted halogen carbon glycosides comprises a chemical reaction of 2-chloromethyl-3-trimethylsilyl-1-propene (SAF Bulk Chemicals), or 2-chloromethyl-3-trimethoxysilyl-1-propene (SAF Bulk Chemicals), or 2-chloromethyl-3-trimethoxysilyl-1-propene by Gelest Inc. (U.S. Patent No.: 3,696,138), with an activated carbohydrate and a Lewis acid, whereby the allylsilanes undergo addition to the pyranose oxonium ions produced by Lewis acid catalysis for example with anomeric acetates. Nashed and Anderson, 1982, Amer. Chem. Soc. 104:7282; Panek and Sparks, 1989, J. Org. Chem. 54:2034. Other electrophilic sugars can be employed as stated earlier (Postema, 1995, *supra*). It will be apparent to those of ordinary skill in the art, that also other functional groups at the C-1 position can be used to convert the anomeric hydroxyl functionality into an appropriate leaving group at the C-1 position can be used to convert the anomeric hydroxyl functionality into an appropriate leaving group to form the oxonium ion. 2-chloromethyl-3-trimethylsilyl-1-propene and 2-chloromethyl-3-trimethoxysilyl-1-propene exhibit about the same efficiency on the benzyl protected carbohydrates, while at least under the specific reaction conditions employed the per-O-acetylated carbohydrates used the 2-chloromethyl-3-trimethylsilyl-1-propene reagent.

The Carbon glycoside Formation with Benzyl Protected Sugar.


2-Chloromethyl-3-(tri-O-benzyl α -L-C-fucopyranoside)-1-propene (3)

5 To a stirred solution of 500 g of
2,3,4-tri-O-benzyl-L-fucopyranose (1.15 mole)
(Pfanstiehl, Inc.) in 500 ml 1,2-dichloroethane or 550
ml THF, 240 ml acetic anhydride, 135 ml pyridine was
added, and the mixture stirred at room temperature for
10 22 hours. Subsequently, the reaction was diluted with
ethyl acetate, washed with water, saturated with sodium
bicarbonate and again with water. The solvents were
moved in vacuo and azeotroped with toluene. The white
solid was placed on a vacuum line, which afforded 542 g
15 (99%) of 1-O-Acetyl-2,3,4-tri-O-benzyl-L-fucopyranose as
a colorless crystalline solid in a mixture of anomeric
acetates, mp=86-87.5°C. 564.35 g 1-O-Acetyl-2,3,4-tri-O-
benzyl-L-fucopyranose (1.19 moles, 1.00 eq.) and 214.6
ml 2-chloromethyl-3-trimethylsilyl-1-propene (1.19 mole,
20 1.00 eq.) were dissolved in 1.2 l acetonitrile (HPLC
grade) and cooled to approximately 0°C using a n ice-
water bath. Subsequently, 11.46 ml
trimethylsilyltrifluoromethane sulfonate (59.28 mmoles,
0.05 eq.) was carefully added, the ice-water bath was
25 allowed to melt and the reaction slowly warmed to room
temperature (18 hours). Completion of the
transformation from starting material to product was
indicated by TLC. The reaction was terminated by
pouring the reaction contents onto 1 l of ice-water,
30 followed by adjustment to room temperature. The

resulting mixture was extracted with 1 l ethyl acetate and the organic phase then washed with 1.0 N aqueous sodium hydroxide and brine. The organic phase was dried over anhydrous magnesium sulfate, filtered, and the solvent was removed in vacuo, which afforded 600.5 g of 2-Chloromethyl-3-(tri-O-benzyl- α -L-C-fucopyranoside)-1-propene (1) as light yellow solid. The product was purified either by crystallization in methanol at 0°C, or by column chromatography using Baker grade flash silica gel (47-61mm) (ratio of 20 to 1), followed by elution with 5 to 10% ethyl acetate in hexanes giving a white solid (98%), mp 47-49°C. In low scale reactions, the α - to β - ratios of the C-glycosidation reaction, was > 10:1 in favor of the α -fucose derivative (Cha, et al., 1982, J. Am. Chem. Soc. 104:4976). The higher the reaction scale, the less β isomer could be observed; at scales in the multi-gram levels, sometimes only trace amounts.

The results of this study are complementary to related C-glycoside formation reactions for pyranosides using an allylic silane and an activated glycal. In another preferred embodiment, the Finkelstein exchange of the chloride for iodide (97% yield) or bromide (95% yield) was performed under standard conditions such as NaI in refluxing acetone or LiBr in refluxing THF. The course of the reaction was monitored by TLC or NMR techniques. Under certain conditions, bromide appears to be more stable than the corresponding iodide and seems to result in higher yielding alkylations.

This preferred method of forming C-glycosides with the benzyl protected sugar, 1-O-acetyl-2,3,4-tri-O-benzyl-L-fucopyranoside is reflected in the following scheme:



5 The following are typical scales of this reaction:
 Starting material Acetate/2-chloromethyl-3-trimethylsilyl-1-propene(310 g/118 ml), Product obtained (331 g); Acetate/2-chloromethyl-3-trimethylsilyl-1-propene(380 g/144 ml), Product obtained (400 g).

10 An alternate procedure starting from the anomeric hydroxyl can be done as follows: To a solution of 20 g tri-O-benzyl-L-fucopyranose (46.03 mmole, 1.00 mmole equiv.) in 200 ml anhydrous acetonitrile 30.0 g 2-chloromethyl-3-trimethylsilyl-1-propene (184.34 mmole, 4.00 mmole equiv.) at 0°C. 10.24 g trimethylsilane trifluoromethane sulfonic acid (46.03 mmol, 1.00 mmole equiv.) was added dropwise in 30 ml anhydrous
 15 acetonitrile (overall reaction concentration 0.2M) and the reaction contents stirred at 0°C for 30 minutes.

After 30 minutes, the reaction was diluted with 230 ml ethyl acetate and terminated by pouring the contents slowly into saturated sodium bicarbonate. The heterogenous layers were separated and the organic phase was washed twice with portions of water, 1.0 M hydrochloric acid and brine. The crude product was dried over anhydrous sodium sulfate, filtered and plugged through a small pad of silica gel. The solvent was removed in vacuo which afforded an oil that was chromatographed on Baker grade flash silica gel (47-61mm; ratio of 50 to 1) and eluted with 5 to 10% ethyl acetate in hexanes. Concentration in vacuo afforded 20.01 g of 2-chloromethyl-3-(tri-O-benzyl- α -L-C-fucopyranoside)-1-propene (85%). MW=507, $[\alpha]_D$: -27.37, C=0.95 in CHCl_3 . A second product, α -L-2,3,4-tri-O-benzyl-fucopyranose- α -L-2,3,4-tri-O-benzyl-fucopyranose.

The product gave the following analytical data:
Reaction yield: 91%, mp=47-49°C. $^1\text{H-NMR}$ (CDCl_3) δ 7.20-7.50 (m, 15H, aromatics), 5.2 (d, J=47.9 Hz, 2H, terminal vinyl), 4.50-4.90 (complex multiplet, 6H, benzylic), 4.25 (p, 1H, H-1), 4.10 (s, 2H, $-\text{CH}_2\text{Cl}$), 3.90 (m, 1H), 3.75 (s, 1H), 2.50 (m, 2H), 1.25 (d, 3H). $^{13}\text{C-NMR}$ (CDCl_3) δ 142.68 alkene (e), 138.62 aromatic (e), 138.29 aromatic (e), 138.11 aromatic (e), 128.17 aromatic (o), 127.86 aromatic (o), 127.45 aromatic (o), 127.34 aromatic (o), 116.28 alkene (e), 76.58 (o), 75.95 (o), 73.24 (e), 72.97 (e), 68.33 (o), 48.23 $-\text{CH}_2\text{Cl}$ (e), 30.30 allylic (e), 15.38 fucose methyl (o). Mass Spec. (LSIMS with mNBA) 505.1/507.3. Analytical Calculated


for $\text{CH}_3\text{H}_3\text{ClO}_4$: C, 73.43; H, 6.96. Found: C, 73.16; H, 7.12.

Example 4

2-Chloromethyl-3-(tetra-O-benzyl- α -L-C-glucopyranocide)-

5 1-propene (4)

In another preferred embodiment,
1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranose was
subjected to the same reaction conditions as have been
described for L-fucopyranoside, resulting in the α -C-
10 glycosides of glucose (91%, mp=79-81°C), as reflected
below:



In general, the reagent ratios for the remaining
per-O-acetylated carbohydrates were for example:
1,2,3,4,6-penta-O-acetyl-D-galactopyranoside (1.00 mmole
15 equiv.) and 2-chloromethyl-3-trimethylsilyl-1-propene
(2.00 mmole equiv.) were dissolved in acetonitrile
(1.3M). Boron trifluoride etherate (2.00 mmole equiv.)
and trimethylsilyltrifluoromethane sulfonate (0.40 mmole
equiv.) were carefully added neat at room temperature.
20 The reaction was refluxed for 6 hours and worked up as
described. TLC 30% ethyl acetate in hexanes.

The glucose product (4) gave the following analytical data:


Reaction yield: 91%, mp=79-81°C. ¹H-NMR (CDCl₃) δ 7.10-7.40 (20H), 5.1 (d, J=41.3 Hz, 2H, terminal vinyl), 4.96
5 (d, 10.87 Hz, 1H), 4.82 (d, 10.87 Hz, 1H), 4.82, (d, J=10.56 Hz, 1H), 4.63 (d, J=12.15 Hz, 1H), 4.44 (d, J=12.15 Hz, 1H), 4.45 (d, J=1.56 Hz, 1H), 4.67 (q, J=11.6 Hz, 2H), 4.24 (p, J=5.07 Hz, 1H, H-1), 4.12 (s, 2H), 3.68 (m, 6H, ring), 2.65 (m, 2H). ¹³C-NMR (CDCl₃) δ
10 142.32 alkene (e), 138.68 (e), 138.08 (e), 137.93 (e), 128.5 (o), 128.0 (o), 127.8 (o), 127.5 (o), 116.95 alkene (e), 82.31 ring (o), 79.85 ring (o), 77.91 ring (o), 75.56 (e), 75.16 (e), 73.46 (e), 73.19 (e), 72.80 ring (o), 71.31 ring (o), 68.79CH₂ ring (e), 48.15 CH₂Cl
15 allylic (e), 27.98 allylic (e). Mass Spec. (LSIMS with mNBA and NaOAc) 635.2 (MNa⁺). Analytical Calculated for C₃₈H₄₁ClO₅: C, 74.43; H, 6.74. Found: C, 74.62; H, 6.92.

Example 5

2-Chloromethyl-3-(2,3,4,6-tetra-O-benzyl-D-galactopyranoside)-1-propane (5)

In another preferred embodiment, 1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-galactopyranose were subjected to the same reaction conditions as have been described

for L-fucopyranoside, resulting in the α -C-glycosides of galactose (5) (84%, oil), as reflected below:




The product gave the following analytical data:

Reaction yield: 84%, and the compound isolated as an
5 oil. $^1\text{H-NMR}$ (CDCl_3) δ , 7.25 (m, 20H), 5.16 (d, $J=37.54$ Hz, 2H), 4.85-4.50 (overlapping benzylic patterns, 6H), 4.26 (p, 3.85 Hz, 1H, H-1), 4.16 (s, 2H), 4.09 (m, 2H), 3.88 (m, 2H), 3.79 (dd, $J=4.88$ Hz, 1H), 2.59 (m, 2H).
 $^{13}\text{C-NMR}$ (CDCl_3) δ 143.32 alkene (e), 139.21 (e), 139.09
10 (e), 138.90 (e), 138.83 (e), 128.5 (o), 128.0 (o), 127.8 (o), 127.5 (o), 117.22 alkene (e), 77.32 ring (o), 74.89 ring (o), 74.00 (e), 73.88 (e), 73.83 (e), 73.69 (e), 72.72 (o), 68.19 (e), 49.09 (e), 28.98 allylic (e).
Mass Spec. (LSIMS with mNBA and NaOAc) 635.3 (MNa^+).
15 Analytical Calculated for $\text{C}_{38}\text{H}_{41}\text{ClO}_5$: C, 74.43; H, 6.74.
Found: C, 74.31; H, 6.87.

Example 62-Iodomethyl-3-(2,3,4,-tri-O-benzyl- α -L-C-fucopyranoside)-1-propene (6)

331 grams of 2-chloromethyl-3-(tri-O-benzyl- α -L-C-fucopyranoside)-1-propene (653 mmole, 1 mmole equiv.)
5 was added to a stirred suspension of 480 g NaI (3222 mmole, 5 mmole equiv.) in 3 l acetone; the reaction was heated to reflux for 3 hours and then allowed to cool to room temperature. Completion of the reaction was
10 monitored by TLC assay. The TLC conditions used were 10% ethyl acetate in hexanes (v/v). The reaction was complete when the product Rf was slightly higher than starting material. The reaction contents were poured into cold water and extracted with EtOAc. The organic
15 layer was washed twice with saturated cold sodium thiosulfate, saturated NaHCO₃, and with water. The product was dried over anhydrous sodium sulfate and filtered to remove the drying agent. The solvent was removed in vacuo which afforded a light yellow waxy
20 solid. Then, the product was dissolved in THF and then concentrated in vacuo twice at low temperatures to remove any residual solvents not desired for the next step to afford 380 grams of 2-Iodomethyl-3-(tri-O-benzyl- α -L-C-fucopyranoside)-1-propene (6) (97%). This
25 material should be protected from heat and light, and used immediately. A typical scale for this reaction is: 331 g starting material, resulting in a yield of 380 g Product.

The product is depicted below:



Example 7

2,3,4-Tri-O-benzyl-α-L-C-Fucopyranoside allylbromide reagent (7)

- 5 To a stirred suspension of 42.72 g LiBr (493 mmole, 5 mmole equiv.) in 197 ml THF 50.0 g 2-chloromethyl-3-(tri-O-benzyl-α-L-C-fucopyranoside)-1-propene (98.6 mmole, 1 mmole equiv.) was added and the reaction was heated to reflux for 3 hours, and then allowed to cool
- 10 to room temperature. The reaction was complete as assayed by TLC (product R_f slightly higher than starting material). The TLC conditions used were 10% ethyl acetate in hexanes (v/v). The reaction contents were concentrated to half of the original volume of THF,
- 15 poured into cold water and then extracted with EtOAc. The organic layer was washed twice with water, 1.0M HCl and again with water. The product was dried over anhydrous sodium sulfate and filtered to remove the drying agent. The solvent was removed in vacuo which
- 20 afforded a light yellow solid. The product was dissolved in methanol and then concentrated in vacuo at low temperatures twice to remove any residual solvents.


The product was dissolved in 150 ml warm methanol and cooled to 0°C overnight. Filtration of the solids results in 40.8 grams as a white crystalline solid. Concentration of the mother liquors to half of the original volume and again cooling to 0°C overnight gave an additional 10.87 grams of a white crystalline solid. Combined recovery yielded 51.67 g of 2-bromomethyl-3-(2,3,4-tri-O-benzyl- α -L-C-fucopyranoside)-1-propene; mp=51.5-53°C, (95%).

10 The product gave the following analytical data:
 $^1\text{H-NMR}$ (CDCl_3) δ 7.20-7.50 (m, 15H, aromatics), 5.2 (d, $J=61.5$ Hz, 2H, terminal vinyl), 4.50-4.90 (complex multiplet, 6H, benzylic, 4.25 (p, $J=4.22$ Hz, 1H, H-1), 4.04 (d, $J=3.1$ Hz, 2H, $-\text{CH}_2\text{Br}$), 3.90 (m, 1H), 3.75 (s, 1H), 2.50 (m, 2H), 1.25 (d, 3H). $^{13}\text{C-NMR}$ (CDCl_3) δ 1423.11 alkene (e), 138.77 aromatic (e), 138.53 aromatic (e), 138.26 aromatic (e), 128.17 aromatic (e), 127.86 aromatic (o), 127.45 aromatic (o), 127.34 aromatic (o), 117.00 alkene (e), 76.69 (o), 76.16 (o), 73.46 (e), 73.11 (e), 69.9 (o), 68.46 (o), 37.03 $-\text{CH}_2\text{Br}$ (e), 30.54 allylic (e), 15.61 fucose methyl (o). Analytical
15 Calculated for $\text{C}_{31}\text{H}_{35}\text{BrO}_4$: C, 67.51; H, 6.40. Found: C, 67.81; H, 6.56.

In general, the reagent ratios for the remaining
25 per-O-acetylated carbohydrates were for example:
1,2,3,4,6-penta-O-acetyl-D-galactopyranoside (1.00 mmole equiv.) and 2-chloromethyl-3-trimethylsilyl-1-propene (2.00 mmole equiv.) were dissolved in acetonitrile (1.3M). Boron trifluoride etherate (2.00 mmole equiv.)
30 and trimethylsilyltrifluoromethane sulfonate (0.400

mmole equiv.) were carefully added neat at room temperature. The reaction was refluxed for 6 hours and worked up as described. TLC 30% ethyl acetate in hexane.

5

Example 8The Carbon Glycoside Formation with Acetyl Protected Sugar:2-Chloromethyl-3-(tri-O-acetyl- α -L-C-fucopyranoside)-1-propene (8)

- 10 50.0 g 1,2,3,4-tetra-O-acetyl-L-fucopyranose (5) (150.5 mmole, 1.00 mmole equiv.) and 36.7 g (40.9 ml) 2-chloromethyl-3-trimethylsilyl-1-propene (225.7 mmole, 2.00 mmole equiv.) were dissolved in 116 ml acetonitrile; subsequently, 74.8 g boron trifluoride etherate (526.8 mmole, 3.50 mmole equiv.) and 13.4 g (11.6 ml) trimethylsilyltrifluoromethanesulfonate (60.2 mmole, 0.40 mmole equiv.) were carefully added after the addition of the Lewis acids (preferentially trimethyltrifluoromethanesulfonate and boron trifluoride
- 15

etherate), the reaction was slowly warmed to reflux and maintained at reflux for 6 hours. The reaction was terminated by cooling to room temperature, pouring the reaction contents on 100 ml of water, followed by
5 extraction of the crude α -C-glycoside with ethyl acetate. The heterogenous layers were separated and the organic phase was washed with portions of water, saturated sodium bicarbonate, 1.0 M hydrochloric acid and brine. The crude extract was dried over anhydrous
10 sodium sulfate, filtered, and the solvent was removed in vacuo to afford an oil that was purified by column chromatography on Baker grade flash silica gel (47-61mm) (ratio of 20 to 1), eluted with 10% ethyl acetate in hexanes. Concentration in vacuo afforded 46.4 g of 2-
15 chloromethyl-3-(2,3,4-tri-O-acetyl- α -L-C-fucopyranoside)-1-propene (85%, oil).

Under these reaction conditions, the 1,2,3,4-tetra-O-acetyl-L-fucopyranoside reaction mixture turned a dark brown to black color, and TLC monitoring showed the
20 transformation from starting material to the α -C-glycoside proceeded as expected. Two compounds, distinguishable by TLC, were isolated by column chromatography on silica gel by elution with 10% ethyl acetate in hexane. As determined by NMR analysis, the
25 major compound was the 2,3,4-tri-O-acetyl- α -C-L-fucopyranoside (85%), and a minor compound was a small amount of starting material. The baseline material observed by TLC probably representing a third unidentified molecule.

The product gave the following analytical data:


Reaction yield: 85%, and the compound isolated as an oil: ¹H-NMR (CDCl₃) δ, 5.3 (m, 1H), 5.2 (m, 2H), 5.2 (s, 1H), 5.05 (s, 1H), 4.38 (m, J=3.48 Hz, 1H, H-1), 4.09
5 (s, 2H), 3.95 (dq, J=1.71 Hz and 4.70 Hz, 1H), 2.6 (dd, J=11.39 Hz, 1H), 2.4 (dd, J=3.42 Hz, 1H), 2.15 (s, 3H), 2.05 (s, 3H), 1.98 (s, 3H), 1.09 (d, J=6.41 Hz, 3H). ¹³C-NMR (CDCl₃) δ 171.03 acetyl (e), 170.66 acetyl (e), 170.38 acetyl (e), 142.06 alkene (e), 117.72 alkene (e),
10 71.66 ring (o), 71.19 ring (o), 68.94 ring (o), 68.40 ring (o), 66.33 ring (o), 48.51 allylic (chloride side) (e), 29.50 allylic (e), 20.77 (o), 20.71 (o), 20.64 (o), 16.53 L-fucose methyl group (o). IR 2985, 1746, 1646 cm⁻¹. Mass Spec. (LSIMS with mNBA and NaOAc) 385.1 (MNa⁺),
15 363.2 (MH⁺). Analytical Calculated for C₁₆H₂₃ClO₇: C, 52.97; H, 6.39. Found: C, 52.66; H, 6.40.

Example 9

Deprotection of Fucose:

The deprotection of the fucose reagent was done in
20 methanol with a catalytic amount of sodium metal added to the stirring methanol. The reaction was terminated by the careful addition of 1.0M HCl until the pH was approximately 2. The solvent was removed in vacuo. The

deprotected fucose is reflected in the following structure:



The product gave the following analytical data:

The reaction was quantitative, mp=185-186.5°C. ¹H-NMR (CDCl₃) δ, 5.02 (d, J=42.8, 2H, terminal vinyl), 4.01 allylic-CH₂Cl (s, 2H), 3.89 (p, J=3.91 Hz, 1H, H-1), 3.69 (m, 2H, H-2 & 5), 3.45 (m, 2H, H-3 & 4), 2.36 (m, 2H, allylic), 0.97 (d, J=6.47 Hz, 3H). ¹³C-NMR (CD₃OD) δ 145.35 alkene (e), 117.18 alkene (e), 75.35 ring (o), 72.84 ring (o), 72.34 ring (o), 69.88 ring (o), 69.15 (o), 49.34 -CH₂Cl (e), 29.50 allylic (e), 17.05 L-fucose methyl (o). Mass Spec. (LSIMS with Gly) 237.1 (MH⁺). Analytical Calculated for C₁₀H₁₇ClO₄: C, 50.74; H, 7.24. Found C, 50.63; H, 7.43.


15

Example 10

2-Chloromethyl-3-(tetra-O-acetyl-α-L-C-glucopyranoside)-1-propene (10)

The reaction conditions used for the α-C-glycosidation of 1,2,3,4-tetra-O-acetyl-L-fucopyranoside were applied to 1,2,3,4,6-penta-O-acetyl-D-glycopyranose, and yielding the expected α-C-glycosides of α-C-glucose (20%). NMR analysis of the α-C-glycoside

carbon shifts (CDCl_3) for the added C-3 unit in the acetyl protected sugars showed a chemical shift around δ 48 for the $-\text{CH}_2\text{Cl}$ allylic carbon and δ 28 for the allylic carbon which forms the C-glycoside at the C-1. 5 carbonylate position, and the alkene shifts were around δ 142 and δ 117. The carbon shifts for the allylic chloride side chain in the benzylated sugars and in the acetyl protected sugars were comparable. The α -carbon glycoside derivative of glucose is shown below:



10 The product gave the following analytical data:
 Reaction yield: 20%, and the compound isolated as an oil. $^1\text{H-NMR}$ (CDCl_3) δ , 5.26 (t, $J=9.10$ Hz, 1H, H-3), 5.10 (d, $J=45.12$ Hz, 2H, terminal vinyl), 5.02 (m, 1H, H-3), 5.10 (d, $J=45.12$ Hz, 2H, terminal vinyl), 5.02 (m, 15 1H, H-2), 4.90 (t, $J=8.97$ Hz, 1H, H-4), 4.33 (m, 1H, H-1), 4.13 (dd, $J=5.44$ Hz, 1H, H-6), 3.98 (dd, $J=2.62$ Hz, 1H, H-6), 4.05 (s, 2H, $-\text{CH}_2\text{Cl}$), 3.86 (m, 1H, H-5), 2.61 (dd, $J=11.54$ Hz, 1H), 2.38 (dd, $J=3.17$ Hz, 1H), 1.99 (s, 3H, acetyl), 1.98 (s, 3H, acetyl), 1.96 (s, 3H, acetyl), 20 1.95 (s, 3H, acetyl). $^{13}\text{C-NMR}$ (CDCl_3) δ 172.03 acetyl (e), 171.54 acetyl (e), 171.04 acetyl (e), 170.99 acetyl (e), 142.33 alkene (e), 118.96 alkene (e), 72.55 ring

(o), 71.57 ring (o), 71.43 ring (o) 70.49 ring (o),
70.13 ring (o), 63.63 C-6 ring (e), 49.29 -CH₂Cl (e),
30.15 allylic (e), 22.11 acetyl groups (o), 22.06 acetyl
groups. IR 2958, 1729, 1646 cm⁻¹.


5

Example 112-Chloromethyl-3-tetra-O-acetyl- α -L-C-
galactopyranoside)-1-propene (11)

The reaction conditions used for the α -C-
glycosidation of 1,2,3,4-tetra-O-acetyl-L-fucopyranoside
10 were applied to the 1,2,3,4,6-penta-O-acetyl-D-
galactopyranose yielding the expected α -C-glycosides of
 α -C-galactose (74%). 1,2,3,4,6-penta-O-Acetyl-D-
galactopyranoside (1.00 mmole equiv.) and 2-
chloromethyl-3-trimethylsilyl-1-propene (2.00 mmole
15 equiv.) were dissolved in acetonitrile (1.3m). Boron
trifluoride etherate (2.00 mmole equiv.) and
trimethylsilyltrifluormethane sulfonate (0.40 mmole
equiv.) were carefully added neat at room temperature.
The reaction was refluxed for 6 hours and worked up as
20 described; TLC: 30% ethyl acetate in hexanes.

NMR analysis of the α -C-glycoside carbon shifts
(CDCl₃) for the added C-3 unit in the acetyl protected
sugars showed a chemical shift around δ 48 for the -CH₂Cl
allylic carbon and δ 28 for the allylic carbon which
25 forms the C-glycoside at the C-1 carbohydrate position,
and the alkene shifts were around δ 142 and δ 117. The
carbon shifts for the allylic chloride side chain in the
benzylated sugars in the acetyl protected sugars were

comparable. The α -carbon glycoside derivative of galactose is shown below:




The product gave the following analytical data:

Reaction yield: 74%, mp=80-82°C. $^1\text{H-NMR}$ (CDCl_3) δ , 5.31
 5 (br, 1H), 5.16 (m, 2H), 5.05 (d, $J=47.17$ Hz, 2H, terminal vinyl), 4.33 (m, $J=3.54$, 1H, H-1), 4.1-3.9 (m, 3H), 4.02 (s, 2H), 2.52 (dd, $J=11.41$, 1H), 2.28 (dd, $J=2.75$, 1H), 2.01 (s, 3H, acetyl), 1.98 (s, 3H, acetyl), 1.91 (s, 6H, acetyl). $^{13}\text{C-NMR}$ (CDCl_3) δ 170.18 acetyl
 10 (e), 169.81 acetyl (e), 169.97 acetyl (e), 169.53 acetyl (e), 141.04 alkene (e), 117.17 alkene (e), 70.64 ring (o), 68.09 ring (o), 67.79 ring (o), 67.55 ring (o), 67.42 ring (o), 62.32 C-6 ring (e), 47.65 $-\text{CH}_2\text{Cl}$ (e), 28.86 allylic (e), 20.53 acetyl group (o), 20.47 acetyl
 15 group (o), 20.41 acetyl group (o). IR 2958, 1729, 1646 cm^{-1} . Mass Spec. (LSIMS with mNBA and NaOAc) 443.1 (MNa^+), 421.2 (MH^+). Analytical Calculated for $\text{C}_{18}\text{H}_{25}\text{ClO}_9$: C, 51.37; H, 5.99. Found: C, 51.47; H, 6.15.

Example 122-Chloromethyl-3-tetra-O-acetyl- α -L-C-mannosopyranoside)-1-propene (12)

The reaction conditions used for the α -C-
5 glycosidation of 1,2,3,4-tetra-O-acetyl-L-fucopyranoside
were applied to 1,2,3,4,6-penta-O-acetyl-D-mannopyranose
yielding the expected α -C-glycoside of α -C-mannose
(80%).

NMR analysis of the α -C-glycoside carbon shifts
10 (CDCl₃) for the added C-3 unit in the acetyl protected
sugars showed a chemical shift around δ 48 for the -CH₂Cl
allylic carbon and δ 28 for the allylic carbon which
forms the C-glycoside at the C-1 carbohydrate position,
and the alkene shifts were around δ 142 and δ 117. The
15 carbon shifts for the allylic chloride side chain in the
benzylated sugars and in the acetyl protected sugars
were comparable. The α -carbon glycoside derivated of
mannose is shown in the following scheme:



The product gave the following analytical data:

Reaction yield: 80%, (compound isolated as an oil).

¹H-NMR (CDCl₃) δ 5.13 (m, 3H), 5.12 (d, J=41.76 Hz, 2H, terminal vinyl, 4.20 (q, J=6.41 Hz, 1H, H-1), 4.05 (m, 2H), 4.04 (d, J=1.65 Hz, 2H, 3.85 (m, J=269 Hz, 1H), 2.60 (dd, J=10.32 Hz, 1H), 2.39 (dd, J=4.52 Hz, 1H), 2.39 (dd, J=4.52 Hz, 1H), 2.03 (s, 3H, acetyl), 1.98 (s, 3H, acetyl), 1.93 (s, 3H, acetyl). ¹³C-NMR (CDCl₃) δ 170.28 acetyl (e), 169.89 acetyl (e), 169.66 acetyl (e), 169.37 acetyl (e), 140.43 alkene (e), 117.61 alkene (e), 73.06 ring (o), 70.52 ring (o), 70.07 ring (o), 68.47 ring (o), 66.52 ring (o), 62.04 CH₂ (e), 47.47 - CH₂Cl (e), 31.95 allylic (e), 20.67 acetyl CH₃ (o), 20.50 acetyl CH₃ (o), 20.47 acetyl CH₃ (o), 20.43 acetyl CH₃ (o). IR 2958, 1729, 1646 cm⁻¹. Mass Spec. (LSIMS with mNBA and NaOAc) 443.0 (MNA⁺), 421.3 (MH⁺).

Example 13

Preparation Of 1-Deoxy-1-α-(2-Carboxy-Naphthyl-6-Oxyethyl)-L-Fucose (13)

20 A solution of ethyl 6-hydroxyl-2-naphthate (49, 89 mg, 0.42 mmole) (6-hydroxy-2-naphthoic acid was obtained from TCI America and converted to the ester using standard esterification methods) and iodide (2, 177 mg, 0.42 mmole) in dimethylformamide (1 ml) was stirred with 25 potassium carbonate (174 mg) for 14 hours. The reaction mixture was worked up with water (30 ml) and ethyl acetate (100 ml). The organic layer was washed with brine (30 ml), dried over sodium sulfate, filtered and

concentrated. The crude product was purified on a silica gel column (hexane ethyl acetate, 4:1) to provide the triacetate of 3 (120 mg, 55%).

A solution of the triacetate in methanol (30 ml) was stirred with 1 Normal sodium hydroxide (3 ml) for 4 hours. The mixture was acidified with 6N hydrochloride and solid collected by filtration. This solid was washed with water, ethyl acetate and suction dried to provide naphthoic acid (13) (24 mg).

10

Example 14

Preparation Of 3,7-Di-(1-Deoxy-1- α -Fucosyl-Ethyleneoxy)-2-Naphthoic Acid (14)

A solution of ethyl 3,7-dihydroxy-2-naphthoate (62 mg, 0.26 mmole (the acid was obtained from Aldrich and it was converted to the ester using standard techniques) 2 mg, and iodide 2 (242 mg) in dimethylformamide (0.5 ml) was heated at 55°C with potassium carbonate (175 mg) for 4 hours. An additional amount of the iodide 2 (80 mg) was added to the mixture which was heated at 55°C overnight. The mixture was worked up with water (50 ml) and ethyl acetate (2 x 75 ml). The ethyl acetate extracts were washed with brine (30 ml), dried over sodium sulfate, filtered and concentrated. The crude product was purified on a silica gel column (hexane: ethyl acetate, 1.5:1) to provide the triacetate of 17 (130 mg, 65% yield).

A solution of the triacetate (120 mg) in methanol (1 ml) was stirred with of 2N potassium hydroxide (1.1 ml) at room temperature overnight. This was acidified

with 6N hydrochloride solution and concentrated to dryness. The residue was dissolved in methanol (10 ml) and solid removed by filtration. The filtrate was concentrated to provide naphthoic acid (14) (70 mg).

5

Example 15Preparation Of 3,5-Di-(1-Deoxy-1- α -Fucosyl-Ethyleneoxy)-2-Naphthoic Acid (15)

When ethyl 3,5-dihydroxy-2-naphthoate (prepared by esterification of the corresponding acid) is substituted
10 for ethyl 3,7-dihydroxy-2-naphthoate in Example 14, the identical process afforded the naphthoic acid (15).

Example 16Preparation Of 6-(1-Deoxy-1- α -Fucosyl-Ethyleneoxy)- α -Methyl-2-Naphthalene Acetic Acid (16)

15 6-Hydroxy- α -methyl-2-naphthaleneacetic acid methyl ester is prepared from 6-methoxy- α -methyl-2-naphthaleneacetic acid by first converting the methyl ether to a hydroxyl group utilizing refluxing 48% HBr/AcOH (Greene and Wuts) and then preparing the
20 corresponding methyl ester utilizing diazomethane.

The iodide 2 (286.6 mg) and 6-hydroxy- α -methyl-naphthaleneacetic acid methyl ester (154.0 mg) were dissolved in dimethylformamide (3 ml) and potassium carbonate (277.6 mg) was added. The reaction was
25 stirred at room temperature for 12 hours, after which it was partitioned between water (10 ml) 15 and ethyl acetate (50 ml). The layers were separated and the organics were washed with water (3 x 10 ml) and brine

(10 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated to dryness.

Purification of the residue on silica gel (25% ethyl acetate/hexane) gave the desired triacetate (225.8 mg, 64% yield).

The above triacetate products was dissolved in methanol (1.70 ml) and 2N sodium hydroxide solution (1.70 ml) was added. The reaction was stirred at room temperature for 13 hours, after which it was acidified with 6 N-hydrochloride. After concentrating to dryness, the residue was washed with water and dried under vacuum to give the desired product 19 (167 mg, 100% yield).

Example 17

Preparation Of 6-Glyceroxy- α -Methyl-2-Naphthalene acetic Acid (17)

6-Hydroxy- α -methyl-2-naphthaleneacetic acid methyl ester is prepared from 6-methoxy- α -methyl-2-naphthaleneacetic acid by first converting the methyl ether to a hydroxyl group utilizing refluxing 48% HBr/AcOH (Greene and Wuts) and then preparing the corresponding methyl ester utilizing diazomethane.

Glycidol (2.95 ml) (obtained from Aldrich) and 6-hydroxy- α -methylnaphthaleneacetic acid methyl ester (1.02 g) were dissolved in dimethylformamide (10 ml). Potassium carbonate (3.g) was added and the reaction was stirred at room temperature for 3 days. After diluting with ethyl acetate (100 ml), the reaction was washed with water (5 x 10 ml). The water layer was washed with ethyl acetate (20 ml) and the combined ethyl acetate

layers were washed with brine (20 ml). After concentrating, the residue was purified on silica gel (70% ethyl acetate/hexane) to give the desired methyl ester glycidol adduct (251.5 mg, 19% yield) and the
5 glycidyl ester glycidol adduct (200.3 mg, 13% yield).

The glycidyl ester glycidol adduct was dissolved in methanol (0.6 ml) and 2N sodium hydroxide (0.6 ml) was added. The reaction was stirred at temperature for 23 hours and acidified with 6N hydrochloride. After
10 concentrating the mixture to dryness, the residue was washed with water and dried under vacuum to give the desired product 17 (125.9 mg, 75% yield).

Example 18

1-Deoxy- α -1-Acetylenyl-1,2,4tri-O-Benzyl-1-Fucose (18)

15 A solution of 1-O-acetyl-2,3,4-tri-O-benzyl-L-fucose (10 g, 21 mmol) and bistrimethylsilylacetylene (7.16 g, 42 mmol) in dichloromethane (50 ml) was cooled to -20°C under argon. A solution of tin tetrachloride in dichloromethane (21 mmol, 1 M) was added and the
20 mixture was stirred at -20°C for 1 hour. The reaction was quenched with saturated aqueous sodium bicarbonate (50 ml), extracted with ethyl acetate (3 x 50 ml) and the combined organic layers were washed with saturated aqueous sodium bicarbonate (2 x 10 ml) and brine (20
25 ml), dried (MgSO₄), filtered and concentrated, the residue was purified on silica gel (30% ethyl acetate/hexane) to give the silylacetylenyl fucose (8.1 g, 75% yield). Water (10 ml) followed by potassium flouride (9.16 g, 158 mmol) was added to a solution of

compound 70 (8.1 g, 15.76 mmol) in DMF (30 ml). The mixture was stirred at room temperature (2h), diluted with water (100 ml) and extracted with 30% ethyl acetate/hexane (3 X 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO₄), filtered and concentrated to give compound 18 (6.97 g, 100% yield).

EXAMPLE 19

Preparation of 1-Deoxy-1- α -(m-Carboxy-Phenylethyl)-L-Fucose-Phenylalanine Amide (19)


Carbonyl diimidazole (2.62 g, 16.14 mmol) was added to a solution of m-iodobenzoic acid (4g, 16.14 mmol) in tetrahydrofuran (100 ml), the mixture was stirred at room temperature (45 min). Phenylalanine benzyl ester p-toluenesulfonate (6.90 g, 16.14 mmol) was added, the mixture was stirred (18), and concentrated to dryness. The organic phase was washed with 1N aq. HCL (3X20 ml), saturated aqueous sodium bicarbonate (2X20 ml) and brine (20 ml), dried (MgSO₄) and concentrated to give the amide (4.79 g, 61 % yield).

The amide (1.28 g, 2.63 mmol) and compound 18 (1.16 g, 2.63 mmol) were dissolved in DMF (10 ml). Triethylamine (0.73 ml, 5.26 mmol) was added followed by tetrakis(triphenyl-phosphine) palladium (100 mg) and copper (I)iodide (40 mg). The reaction was stirred at room temperature (6h), diluted with water (100 ml), and extracted with ethyl acetate (3X20 ml). The combined organic phases were washed with 1N aq. HCl (40 ml), saturated aqueous sodium bicarbonate (40 ml) and brine

(40 ml), dried (MgSO_4) and concentrated. The residue was purified on silica gel (20% ethyl acetate/hexane) to give the coupled product (0.6 g, 28% yield).

The coupled product (0.6 g, 0.75 mmol) was dissolved in ethyl acetate (5 ml). 10% Palladium/carbon (0.6 g) was suspended in methanol (40 ml) and the ethyl acetate solution was added via cannula. After stirring under hydrogen for 4 days, the mixture was filtered through Celite and the filtrate was concentrated to dryness giving the title compound 22 (0.24 g, 72% yield).


EXAMPLE 20




2-Naphthol (6.20 g, 43.01 mmol) and tetra-O-acetyl 2-deoxyglucose (14.28 g, 43.01 mmol) were dissolved in acetonitrile (100 mL) and borontrifluoride etherate (10.58 mL) was added. The reaction was stirred at room temperature for 24 hours after which it was quenched with saturated aqueous sodium bicarbonate (100 mL). The resulting mixture was diluted with ethyl acetate (200 mL) and washed with saturated aqueous sodium bicarbonate (2 X 50 mL) and brine (50 mL). After drying over anhydrous magnesium sulfate, the solution was filtered,

concentrated, and purified on silica gel (30% ethyl acetate/hexane) to give the desired product (10.54 g, 59%).


EXAMPLE 21




2-Naphthol (8.72 g, 60.48 mmole) and tetra-O-acetyl
2-deoxygalactose (20.08 g, 60.48 mmole) were dissolved
in acetonitrile (100 mL) and borontrifluoride etherate
(14.88 mL) was added. The reaction and workup were
10 identical to that in example 20 giving the desired
product (16.89 g, 67%).

EXAMPLE 22


2-Naphthol (1.00 g, 7.01 mmole) and tri-O-benzyl 1-O-acetylfucose (2.22 g, 4.67 mmoles) were dissolved in
5 acetonitrile (15 mL) and 4Å molecular sieves (2.00 g) were added. After adding borontrifluoride etherate (1.72) mL), the reaction was stirred at room temperature for three days and quenched with 6N HCl (10 mL). After stirring at room temperature for 2 hours, the reaction
10 was neutralized with saturated aqueous sodium bicarbonate. The resulting mixture was washed with ethyl acetate (2 X 50 mL) and brine (2 X 25 mL). After drying over anhydrous magnesium sulfate, the solution was filtered, concentrated and the product purified on
15 silica gel (10% ethyl acetate/hexane) to give the desired product (2.05 g, 78%).

EXAMPLE 23

6-O-Demethyl naproxen methyl ester (1.00 g, 4.35 mmole) and tri-O-benzyl 1-O-acetylfucose (1.38 g, 2.90 mmole) were dissolved in acetonitrile (10 mL) and 4Å molecular sieves (2.00 g) were added. After adding borontrifluoride etherate (1.07 mL), the reaction was stirred at room temperature for two days and quenched with 6N HCl (10 mL). After stirring at room temperature for 40 minutes, the reaction was neutralized with saturated aqueous sodium bicarbonate. The resulting mixture was washed with ethyl acetate (3 X 20 mL). After drying over anhydrous magnesium sulfate, the solution was filtered, concentrated and the product purified on silica gel (hexane then 10% acetone/hexane then 15% acetone/hexane) to give the desired product (1.44 g, 77%).

EXAMPLE 24


6-O-Demethyl naproxen methyl ester and tetra-O-acetyl 2-deoxygalactose are dissolved in acetonitrile and borontrifluoride etherate is added. The reaction
5 and workup are identical to that in Example 20.

EXAMPLE 25


The product from example 24 and 1-deoxy-1-α-(3-chloromethyl)-2,3,4-tri-O-acetylfucose are dissolved
10 in dimethylformamide and potassium carbonate is added followed by tetrabutyl ammoniumiodide. After stirring at room temperature for 2 days, the reaction is diluted

with ethyl acetate and washed with saturated aqueous sodium bicarbonate (3 X) and brine (2 X). The mixture is dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified on silica gel to
5 give the desired product.

EXAMPLE 26




The product from Example 25 is dissolved in 1,2-dichlorobenzene and heated to 190 degrees C for six
10 hours. After cooling to room temperature, reaction mixture is separated on silica gel giving the desired product.

EXAMPLE 26

Sodium metal (4 spheres) are washed in hexane and added to anhydrous methanol (20 mL). 0.10 mL of the resulting sodium methoxide solution is added to a solution of the product from Example 25. In anhydrous methanol (10 mL). After stirring at room temperature for 24 hours, the reaction is concentrated to dryness giving the desired product.


10

EXAMPLE 27


The product from example 32 is dissolved in methanol and an equivalent volume of aqueous 2N NaOH (2 equivalents) is added. The reaction is stirred at room

temperature for 24 hours and neutralized methanol washed Amberlyst acidic ion exchange resin. Filtration and concentration of the resulting solution provides the desired product.


5

EXAMPLE 28


The product from Example 26 is dissolved in methylene chloride/dimethyl formamide (20/1) and TBDMS-
CI (0.53 g, 3.51 mmoles) is added followed by imidazole
10 (0.34 g, 5.02 mmoles). After stirring at room
temperature for 20 hours, TBDMS-Cl (0.53 g, 3.51 mmoles)
and imidazole (0.34 g, 5.02 mmoles) are added. Stirring
is continued for an additional 20 hours after which, the
reaction is quenched with methanol (10 mL). After
15 stirring for 30 minutes at room temperature, the
reaction is concentrated to dryness and the product is
purified on silica gel.

EXAMPLE 29


The product from Example 28 is dissolved in pyridine and an equivalent volume of acetic anhydride is added. After stirring at room temperature for three days, the reaction is concentrated to dryness and the residue is dissolved in ethyl acetate. After washing with 1N HCl (3 X), saturated aqueous sodium bicarbonate (6 X), water, saturated aqueous copper sulfate (2 X), and brine (10 mL), the organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated to dryness giving the desired product (1.98 g, 81%).

EXAMPLE 30

The product described in Example 29 is dissolved in tetrahydrofuran and tetrabutyl ammonium fluoride (1M in THF) is added. After stirring at room temperature for five days, the reaction is concentrated. Purification of the residue on silica gel gives the desired product.

EXAMPLE 31


The product described in Example 30 and methyl
bromoacetate are dissolved in tetrahydrofuran and sodium
5 hydride (60% in mineral oil) is added. After stirring
at room temperature for 2 days, the reaction is quenched
with saturated aqueous sodium bicarbonate. The reaction
is diluted with ethyl acetate and washed with brine (2
X). After drying over anhydrous magnesium sulfate, the
10 organic phase is filtered and concentrated.
Purification of the residue on silica gel gives the
product.

EXAMPLE 32

15 Sodium metal (4 spheres) are washed in hexane and
added to anhydrous methanol (20 mL). 0.10 mL of the
resulting sodium methoxide solution is added to a


solution of the product from Example 31 in anhydrous methanol. After stirring at room temperature for 24 hours, the reaction is concentrated to dryness giving the desired product.

5

EXAMPLE 33


The product described in Example 32 is dissolved in methanol and an equivalent volume of 2N aqueous sodium hydroxide (4 equivalents) is added. The reaction is stirred at room temperature for 20 hours and neutralized with methanol washed Amberlyst acidic ion exchange resin. Filtration and concentration of the resulting solution provides the desired product.

15


EXAMPLE 34

Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.20 mL of the resulting sodium methoxide solution is added to a


solution of the product from Example 28 in anhydrous methanol. After stirring at room temperature for 24 hours, the reaction is neutralized with amberlite acidic ion exchange resin. After removal of the resin by
5 filtration, the filtrate is concentrated to dryness giving the desired product.

EXAMPLE 35


The product from Example 34 is dissolved in 2,2-
10 dimethoxypropane and camphorsulfonic acid is added. After stirring at room temperature for 24 hours, the reaction is concentrated to dryness. The residue is dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate (3 X) and brine. After
15 drying over anhydrous magnesium sulfate, the organic phase is filtered and concentrated to dryness giving the desired product.

EXAMPLE 36


The product described in Example 35 and 1-deoxy-1-
α-(3-chloromethyl)-2,3,4-tri-O-acetylfucose are
5 dissolved in dimethylformamide and potassium carbonate
is added followed by tetrabutyl ammoniumiodide. After
stirring at room temperature for 6 days, the reaction is
diluted with ethyl acetate and washed with saturated
aqueous sodium bicarbonate (3 X) and brine (2 X). The
10 mixture is dried over anhydrous magnesium sulfate,
filtered and concentrated. The residue is purified on
silica gel to give the desired product.

EXAMPLE 37


15 This product is prepared from the product of
Example 36 using methodology similar to that used in
Example 34.

EXAMPLE 38


This product is prepared from the product of Example 37 using methodology similar to that used in
5 Example 34.

EXAMPLE 39


This product is prepared from the product of example 38 using methodology similar to that used in
10 Example 33.

EXAMPLE 40


The product from Example 39 is dissolved in tetrahydrofuran and an equivalent volume of 6N
5 hydrochloric acid is added. After stirring at room temperature for 24 hours, the reaction is concentrated to dryness to give the desired product.

EXAMPLE 41


10 This product is prepared from the product of Example 40 using methodology similar to that used in Example 26.

EXAMPLE 42


The product from example 20 (10.54 g, 25.34 mmoles) and 1-deoxy-1- α -(3-chloromethyl)-2,3,4-tri-O-acetylfucose (10.09 g, 27.87 mmoles) were dissolved in dimethylformamide (100 mL) and potassium carbonate (7.00 g, 50.67 mmoles) was added followed by tetrabutyl ammoniumiodide (0.94 g, 2.53 mmoles). After stirring at room temperature for 2 days, the reaction was diluted with ethyl acetate (300 mL) and washed with saturated aqueous sodium bicarbonate (3 X 50 mL) and brine (2 X 50 mL). The mixture was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified on silica gel (30% ethyl acetate/hexane) to give the desired product (12.83 g, 68%).

EXAMPLE 43


The product from Example 21 (16.89 g, 40.60 mmoles) and 1-deoxy-1- α -(3-chloromethyl)-2,3,4-tri-O-
5 acetylfucose (15.43 g, 42.63 mmoles) were dissolved in dimethylformamide (100 mL) and potassium carbonate (11.22 g, 81.20 mmoles) was added followed by tetrabutyl ammoniumiodide (1.50 g, 4.06 mmoles). After stirring at room temperature for 2 days, the reaction was diluted
10 with ethyl acetate (300 mL) and washed with saturated aqueous sodium bicarbonate (3 X 50 mL) and brine (2 X 50 mL). The mixture was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified on silica gel (30% ethyl acetate/hexane) to
15 give the desired product (27.12 g, 90%).

EXAMPLE 44


The product from Example 42 (6.13 g, 8.26 mmoles) was dissolved in 1,2-dichlorobenzene (16.60 mL) and heated to 190 degrees C for six hours. After cooling to room temperature, reaction mixture was separated on silica gel giving the desired product (3.23 g, 53%).

EXAMPLE 45


The product from Example 43 (6.38 g, 8.60 mmoles) was dissolved in 1,2-dichlorobenzene (17.00 mL) and heated to 190 degrees C for six hours. After cooling to room temperature, reaction mixture was separated on silica gel giving the desired product (2.28 g, 36%).

EXAMPLE 46


Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.10 mL of the resulting sodium methoxide solution was added to a solution of the product from Example 42 (3.05 g, 4.11 mmol) in anhydrous methanol (20 mL). After stirring at room temperature for 24 hours, the reaction was concentrated to dryness giving the desired product (2.10 g, 100%).

EXAMPLE 47


Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.10 mL of the resulting sodium methoxide solution was added to a solution of the product from Example 43 (4.97 g, 6.70 mmol) in anhydrous methanol (20 mL). After stirring at room temperature for 24 hours, the reaction was concentrated to dryness giving the desired product (3.45 g, 100%).

EXAMPLE 48

Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.10 mL of the resulting sodium methoxide solution was added to a solution of the product from Example 44 (3.23 g, 4.35 mmol) in anhydrous methanol (10 mL). After stirring at room temperature for 24 hours, the reaction was concentrated to dryness giving the desired product (2.14 g, 100%).


EXAMPLE 49

Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.10 mL of the resulting sodium methoxide solution was added to a solution of the product from Example 45 (2.28 g, 3.07 mmol) in anhydrous methanol (10 mL). After stirring at room temperature for 24 hours, the reaction was concentrated to dryness giving the desired product (1.55 g, 100%).

EXAMPLE 50


The product from Example 46 (1.64 g, 3.35 mmoles) was dissolved in methylene chloride (20 mL) and dimethyl
5 formamide (1 mL) and TBDMS-Cl (0.53 g, 3.51 mmoles) was added followed by imidazole (0.34 g, 5.02 mmoles). After stirring at room temperature for 20 hours, TBDMS-Cl (0.53 g, 3.51 mmoles) and imidazole (0.34 g, 5.02
10 mmoles) were added. Stirring was continued for an additional 20 hours after which, the reaction was quenched with methanol (10 mL). After stirring for 30 minutes at room temperature, the reaction was concentrated to dryness and the product was purified on silica gel (10% methanol/chloroform, 1.81g, 90%).

EXAMPLE 51




This product (1.65 g, 46%) was prepared from the compound described in Example 47 using similar
5 conditions to those described in Example 50.


EXAMPLE 52




This product (1.76 g, 80%) was prepared from the compound described in Example 48 using similar
10 conditions to those described in Example 50.

EXAMPLE 53


This product (1.02 g, 64%) was prepared from the compound described in Example 49 using similar
5 conditions to those described in Example 50.

Example 54


The product from Example 50 (1.81 g, 3.00 mmoles) was dissolved in pyridine (5.00 mL) and acetic anhydride (5.00 mL) was added. After stirring at room temperature
10 for three days, the reaction was concentrated to dryness and the residue was dissolved in ethyl acetate (50 mL). After washing with 1N HCl (3 X 10 mL), saturated aqueous sodium bicarbonate (6 X 10 mL), water (10 mL), saturated aqueous copper sulfate (2 X 10 mL), and brine (10 mL),
15 the organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated to dryness giving the desired product (1.98 g, 81%).

EXAMPLE 55


This product (3.04 g, 70%) was prepared from the compound described in Example 51 using similar
5 conditions to those described in Example 54.

EXAMPLE 56


This product (2.07 g, 83%) was prepared from the compound described in Example 52 using similar
10 conditions to those described in Example 54.

EXAMPLE 57


This product (1.24 g, 86%) was prepared from the compound described in Example 53 using similar
5 conditions to those described in Example 54.

EXAMPLE 58


The product described in Example 54 (1.98 g, 2.43
mmoles) was dissolved in tetrahydrofuran (10 mL) and
10 tetrabutyl ammoniumfluoride (1M in THF, 2.68 mL, 2.68
mmoles) was added. After stirring at room temperature
for five days, the reaction was concentrated.
Purification of the residue on silica gel (50% ethyl
acetate/hexane) gave the desired product (1.29 g, 76%).

EXAMPLE 59


This product (0.87 g, 69%) was prepared from the compound described in Example 55 using similar
5 conditions to those described in Example 58.

EXAMPLE 60

This product (0.96 g, 63%) was prepared from the
10 compounds described in Example 56 using similar
conditions to those described in Example 58.




EXAMPLE 62




SUBSTITUTE SHEET (RULE 26)

purified on silica gel (70% ethyl acetate/hexane) giving the product (0.86 g, 65%).

EXAMPLE 63




5 The product described in Example 62 (0.86 g, 120
mmoles) was dissolved in methanol (7.23 mL) and 2N
aqueous sodium hydroxide (7.23 mL) was added. After
stirring at room temperature for 24 hours, the methanol
was evaporated and the aqueous residue was acidified
10 with 6N HCl to pH = 2. The water was then removed on a
lyophilizer. The salt components of the residue were
removed by washing with minimal amounts of methanol and
removing the solids by filtration. Concentration of the
filtrate provided the product (0.62 g, 100%).

EXAMPLE 64


The product described in Example 60 (0.96 g, 1.29
mmoles) and methyl bromoacetate (0.18 mL, 1.94 mmoles)
5 were dissolved in tetrahydrofuran (2.00 mL) and sodium
hydride (60% in mineral oil, 62 mg, 1.55 mmoles) was
added. After stirring at room temperature for 2 days,
the reaction was quenched with saturated aqueous sodium
bicarbonate (10 mL). The reaction was diluted with
10 ethyl acetate (50 mL) and washed with brine (2 X 25 mL).
After drying over anhydrous magnesium sulfate, the
organic phase was filtered and concentrated.
Purification of the residue on silica gel (50% ethyl
acetate/hexane) gave the product (0.53 g, 50%).

15


EXAMPLE 65

Sodium metal (4 spheres) were washed in hexane and
added to anhydrous methanol (20 mL). 0.10 mL of the
resulting sodium methoxide solution was added to a

solution of the product from Example 64 (0.53 g, 0.65 mmols) in anhydrous methanol (10 mL). After stirring at room temperature for 24 hours, the reaction was concentrated to dryness giving the desired product (0.36 g, 99%).


EXAMPLE 66

The product described in Example 65 (0.36 g, 0.64 mmols) was dissolved in methanol (0.64 mL) and 2N aqueous sodium hydroxide (0.64 mL, 1.28 mmols) was added. The reaction was stirred at room temperature for 20 hours and the methanol was removed under reduced pressure. The residue was dissolved in water (20 mL) and the water was removed on a lyophilizer giving the desired product (0.39 g, 100%).

EXAMPLE 67


Sodium metal (4 spheres) were washed in hexane and added to anhydrous methanol (20 mL). 0.20 mL of the resulting sodium methoxide solution was added to a

solution of the product from Example 20 (12.29 g) in anhydrous methanol (20 mL). After stirring at room temperature for 24 hours, the reaction was neutralized with amberlite acidic ion exchange resin. After removal
5 of the resin by filtration, the filtrate was concentrated to dryness giving the desired product (7.90 g, 92%).

EXAMPLE 68

10 The product from Example 67 (7.90 g, 27.24 mmols) was dissolved in 2,2-dimethoxypropane (100 mL) and camphorsulfonic acid (0.32 g, 1.36 mmols) was added. After stirring at room temperature for 24 hours, the reaction was concentrated to dryness. The residue was
15 dissolved in ethyl acetate (300 mL) and washed with saturated aqueous sodium bicarbonate (3 X 50 mL) and brine (50 mL). After drying over anhydrous magnesium sulfate, the organic phase was filtered and concentrated to dryness giving the desired product (8.44 g, 94%).

EXAMPLE 69



The product described in Example 68 (8.44 g, 25.58 mmols) and 1-deoxy-1- α -(3-chloromethallyl)-2,3,4-tri-O-acetylfucose (10.18 g, 28.13 mmols) were dissolved in dimethylformamide (100 mL) and potassium carbonate (7.07 g, 51.15 mmols) was added followed by tetrabutyl ammoniumiodide (0.94 g, 2.53 mmols). After stirring at room temperature for 6 days, the reaction was diluted with ethyl acetate (300 mL) and washed with saturated aqueous sodium bicarbonate (3 X 50 mL) and brine (2 X 50 mL). The mixture was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified on silica gel (50% ethyl acetate/hexane) to give the desired product (14.04 g, 84%).

Example A

Selectin Binding

An ELISA assay was employed that uses recombinant fusion proteins composed of extracellular portions of the human selectins joined to human immunoglobulin heavy chain CH₃, CH₂, and hinge regions. See, for example, Walz et al., Science (1990) 250:1132; Aruffo et al., Cell (1991) 67:35; Aruffo et al., Proc. Natl. Acad. Sci. USA (1992) 89:2292. The assay is well known in the art,

and generally consists of the following three steps:

I. 2,3 sLe^x glycolipid (25 picomole/well) was transferred into microliter well as solutions and then evaporated off. Excess, which remained unattached, was washed off with water. The wells were then blocked with 5% BSA at room temperature for an hour and then washed with PBS containing 1mM calcium.

II. Preparation of "multivalent" receptor of the Selectin-IgG chimera was carried out by combining the respective chimera (1 µg/ml) with biotin labelled goat F(ab')₂ anti-human IgG (Fc specific) and streptavidin-alkaline phosphatase diluted 1:1000 in 1% BSPBS (1 mM calcium) and incubating at 37°C for 15 min. This allowed the soluble multivalent receptor complex to form.

III. Potential inhibitors such as compounds of formula I were allowed to react with the soluble receptor at 37°C for 45 min. This test assumes that optimal binding, between the soluble phase receptor complex and the inhibitor (non-natural ligand), would have occurred within this time frame. This solution was then placed in the microliter wells that were prepared in step I. The plate was incubated at 37°C for 45 minutes to allow the soluble receptor to bind to its natural ligand. In the presence of a strong inhibitor only a few receptors should be free to bind to the microliter plate coated with the natural ligand.

The positive control is the signal produced by the soluble receptor when it is allowed to react with 2,3 sLe^x glycolipid in the microliter wells in the absence of

any inhibitor. This was considered 100% binding. The signal produced by the receptor that had been previously treated with an inhibitor (recorded as O.D.), was divided by the signal produced by the positive control and multiplied by 100 to calculate the % receptor bound to the well, or the percent of control binding. Several of the compounds described herein were tested using this assay. Tables A and B lists the extent to which the invention compounds inhibit binding of E, L and P-selectin to 2,3 sLe^x glycolipid in terms of IC₅₀ values.

In addition to the ligands described above, other ligands could be obtained by selectins more rigid spacers in order to maintain the appropriate statistical average distance between the sialic acid and fucose moieties in space thereby improving the inhibitory property of such structures towards the selectins. Further modifications of these compounds e.g., attaching them through chemical linkages on appropriate molecular supports and use of analogs or derivatives of sialic acid and L-fucose are also considered to be within the scope of the present invention.

Example BFlow Cytometric Assay for P-selectin Ligand

The interaction of P-selectin and its cellular ligand was studied using a flow cytometric assay (Erbe, D.V. et al., J. Cell Biol. (1993) 120:1227). HL60 cells (maintained in high glucose DME plus 10% Hyclone FBS) were used in this assay. Before staining with P-selectin-IgG the cells were preincubated in Dulbecco's PBS/1% BSA/0.1% sodium azide/1% normal rabbit serum (staining medium) for 30-60 mins on ice. After this initial incubation, 1 μ g of P-selectin-IgG was added to 100 μ l aliquots of 10⁶ cells and incubated for 30-60 mins on ice. The cells were then washed with staining medium and resuspended in 100 μ l of staining medium to which was added 2 μ l of a phycoerythrin-conjugated F(ab')² goat anti-human IgG (Fc specific). The cells were incubated for 15-30 mins on ice, washed twice with staining medium, and resuspended in 0.5 ml of staining medium before flow cytometric analysis on a FACScan (Becton Dickinson & Co., Mountain View, CA). To determine that the staining was an interaction of P-selectin with its ligand, the staining was also done in the presence of 10 mM EGTA. To determine the protease sensitivity and the requirement for sialic acid of this interaction, HL-60 cells in D-PBS and 1% BSA were incubated with either trypsin or Arthrobacter or Clostridium sialidases at 37°C before resuspending in staining medium. To examine the ability of various carbohydrates to inhibit staining, 50 μ g/ml fucoidin (Sigma Immunochemicals, St. Louis, MO), 50 μ g/ml dextran

sulfate (Pharmacia Fine Chemicals, Piscataway, NJ), 10 mg/ml mannose-1-phosphate (Sigma Immunochemicals), or 10 mg/ml mannose-6-phosphate (Sigma Immunochemicals) was added to cells immediately before the addition of the P-selectin chimera. Each carbohydrate was then present until the cells were washed before the addition of the second stage antibody. A potential complication of this FACS assay warose from the use of selectin-IgG chimeras to stain cells which bear human IgG Fc receptors (FcYR; Fanger, M.W., et al., Immunol. (1989) 10:92). Adding rabbit IgG (in the form of normal rabbit serum) to the assay medium blocked this binding in most cases. Table 2 shows the results (in terms of %inhibition) of the ability of compounds C and D, 6-O-sulfo-hexanyl- α -L-fuopyranoside, to inhibit P-selectin-IgG binding to HL-60 cells lines. The structure of compounds C is shown below:




Table 2

Compound #	Concentration (mg/ml)	Inhibition (%)
<u>C</u>	10	60
	50	80
	100	80
<u>D</u>	10	50
	100	50
	200	60

Example CTreatment of Sepsis

- 5 A number of the complications associated with sepsis arise from unwanted neutrophil extravasation and adhesion of the neutrophils to the endothelium. The invention compounds would be used to prevent or treat sepsis.
- 10 The effectiveness of these compounds would be shown in a baboon sepsis model system as described by Taylor et al., J. of Clinical Inv., (1987), 79:918, and by Taylor, et al., Circulatory Shock, (1988), 26:227. Briefly this model would consist of determining if the
- 15 compounds are effective in treating sepsis by preventing the death, or prolonging the lives of septic animals to either a lethal or sublethal dose of E. coli. A lethal or sublethal dose of E. coli. consist of approximately 4×10^{10} and 0.4×10^{10} organisms, respectively. Baboons
- 20 that receive a lethal dose of E. coli invariably die

within 16-32 hours. Taylor, et al., J. of Clinical Inv. (1987), 79:918, and Taylor et al., Circulatory Shock, (1988), 26:227.

Thus, the procedure would consist of using two
5 administration routines for each of the compounds tested wherein they are delivered in physiological saline. In the first, between 1 and 10 mg of compound per kg of body weight is administered in three separate doses at 24, 22, and 21 hours before a lethal challenge of
10 bacteria. Alternatively, compound can be administered in a single dose simultaneously with the bacterial challenge. In both instances the compounds would considerably extend the lifetime of the baboons that receive the multiple or single dose treatment and they
15 would survive well beyond 48 hours.

Example D

Reperfusion Injury Assay

Experiments were done to determine the effectiveness of compound C in decreasing adhesion of
20 human neutrophils in the rabbit isolated heart. Addition of the human plasma to the rabbit isolated heart results in activation of the complement components found within the plasma, which in turn promotes an increase in the neutrophil accumulation. This model is
25 used to determine the effect of sLe^x analogues on inhibiting complement-induced neutrophil adhesion.

Hearts from New Zealand White rabbits were excised, mounted on a modified Langendorff apparatus and perfused with Krebs-Heinseleit buffer. Cardiac functional




parameters were monitored upon a Grass Model 79D polygraph machine. 4% normal human plasma (NHP) was added to the recirculating buffer. Ten minutes after the addition of the plasma, Compound C (0.1 20mg/ml) was added to the perfusate. After 15 minutes of perfusion with the plasma, 51-chromium labelled human neutrophils (1×10^5 /ml) were added to the perfusate and allowed to recirculate for an additional 15 minutes. At the end of this time the hearts were washed with fresh buffer to remove non-specifically bound neutrophils, dried and counted in a well type gamma-counter. A concentration response curve was generated using concentrations of 0.001, 0.01 and 0.1 mg/ml. Six hearts were used for each of these concentrations. 30 Percent inhibition of neutrophil accumulation was found. These results are expressed as the number of radiolabelled human neutrophils/mg of dry weight of the heart.

It should also be noted that the greatest degree of inhibition seen using pharmacological agents, including a number of peptides derived from P-selectin and antibodies directed against P-selectin and the CD11b/CD18 complex (Ma, Xin-liang, et al., Circulation (1993) 88-2:649), has been 40%. Compound C provides a degree of inhibition (30%) similar to any of the pharmacological agents tested thus far.

Based on the above results, it is apparent that the compounds of the invention are useful for treating diseases, preferably diseases that have an inflammatory component-Adult Respiratory Distress Syndrome (ARDS), ischemia and reperfusion injury, including strokes,



mesenteric and peripheral vascular disease, organ transplantation, and circulatory shock (in this case one or many organs might be damaged following restoration of blood flow).

TABLE A
Naphthoic Acid C-Glycosides



R ₂	R ₃	R ₅	R ₆	R ₇	E (IC ₅₀ , nM)	L (IC ₅₀ , nM)	P (IC ₅₀ , nM)
CO ₂ H	H	H	OF ₂ ^A	H	< 0.5	< 1.0	< 0.5
CH(CH ₃)CO ₂ H	H	H	OF ₂ ^A	H	> 1.5	> 1.5	> 1.5
CO ₂ H	OF ₂ ^A	H	H	OF ₂ ^A	> 4.0	> 2.0	> 2.0
CO ₂ H	OF ₂ ^A	OF ₂ ^A	H	H	> 4.0	< 2.0	< 0.5
CO ₂ H	OF ₂ ^A	H	O-DF ₂ ^A	H	> 1.5	> 1.5	> 1.5
CO ₂ H	OF ₂ ^A	H	H	O-DF ₂ ^A	> 4.0	< 4.0	< 2.0
CH(CH ₃)CO ₂ H	H	H	OF ₂ ^A	H	> 1.5	> 1.5	> 1.5
CH(CH ₃)CO ₂ H	H	H	OF ₂ ^A	H	> 1.0	> 1.0	> 1.0

TABLE B
Naphthol-C-Glycosides













EXAMPLE	R''	R ₅	R ₆	R ₇	E (IC ₅₀ , mM)	L (IC ₅₀ , mM)	P (IC ₅₀ , mM)
	H		H	F ₁ ^A	Ins	Ins	Ins
	H		F ₁ ^A	H	Ins	Ins	Ins
	H		F ₁ ^A	H	> 4.0	> 4.0	> 4.0
	H		H	F ₁ ^A	> 1.5	> 1.5	> 1.5
	H		F ₁ ^C	H	> 1.5	> 1.5	> 1.5
	CH ₂ CO ₂ H		H	F ₁ ^A	> 2.0	> 2.0	> 2.0

TABLE C



What is claimed:

1. A compound of the formula I:




wherein

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are independently
5 selected from the group consisting of

- (a) -H, Y-B, alkyl of 1 to 4 carbon atoms
optionally substituted with 1 to 2 lower alkyl groups,
-W((CH₂)_n-B)_t, -W((CH₂)_m-(CHR⁹)_q-(CH₂)_n-A)_t;
-OH, lower alkoxy, lower aryloxy, lower aralkoxy,
10 lower alkoxyaryl, amino,
-W((CH₂)_n-A)_t, -O-CH₂-C≡C-B, -N(Ac)-CH₂-C≡C-B, -NH-
CH₂-C≡C-B, -N(CH₂-C≡C-B)₂, -N(Ac)CH₂Ar-B, -NHCH₂Ar-B,
-N(CH₂Ar-B)₂, -OCH₂Ar-B, -(C=O)(CH₂)_m-B,
(b) a direct link to A, and a direct link to B;
15 where

Y-B is selected from the group consisting of


- W(CH₂(C=O)CH₂-B)_t, -W(CH₂(C=C(R¹⁵)₂)-CH₂-B)_t,
-W(CH₂CH-CH₂-B)_t, -W(CH₂CR¹¹-CH₂-B)_t,
20 $\begin{array}{c} | \\ \text{CH}(\text{R}^{11})_2 \end{array}$ $\begin{array}{c} | \\ \text{C}(\text{R}^{11})_2\text{OR}^{11} \end{array}$
 $\begin{array}{c} \text{OR}^{12} \\ | \end{array}$
-W(CH₂-C-CH₂-B)_t, -W(CH₂C(R¹¹)₂-CH₂-B)_t,
25 $\begin{array}{c} | \\ \text{C}(\text{R}^{11})_2\text{OR}^{11} \end{array}$



A is selected from the group consisting of
 -(C=O)R¹¹, sialic acid, Kemp's acid, quinic acid, -B,
 -SO₃M, -OSO₃M, -SO₂NH₂, -PO₃M₂, -OPO₃M₂, -NO₂, saturated or
 10 unsaturated carboxylic acids of 1 to 4 carbon atoms,
 optionally substituted with 1 to 2 hydroxyl groups, and
 esters, and amides thereof;

W is selected from the group consisting of a direct
 link, -O-, -N-, -S-, -NH-, and -NAC-;

B is



15 wherein

U is selected from the group consisting of -R⁹,
 -CH₂OR¹⁰, -CH₂O-protecting group, -COOR¹¹, -CON(R¹¹)₂, and
 -COOM;

R⁹ is lower alkyl;

20 each n is independently selected from the group 0,
 1, 2, and 3;

each m is independently selected from the group 0,
 1, 2, 3, and 4;

each q is independently selected from the group 0, 1, and 2;

each s is independently selected from the group 1, 2, and 3;

5 each z is independently selected from the group 1 and 2;

each t is independently selected from the group 1 and 2, with the proviso that when W is -N, then t is 2, and at all other definitions of W, t is 1;

10 R^{10} is selected from the group consisting of -H, $-R^{11}$, $-SO_3M$, $-(C=O)R^{11}$, $-SO_2NH_2$, $-PO_3M_2$, $-alk-COOR^{13}$, $alk-CON(R^{11})_2$, and -O-carbohydrate;

R^{11} is independently selected from the group consisting of -H, lower alkyl, cyclic alkyl of 5 to 6
15 carbon atoms, heterocyclic alkyl of 4 to 5 carbon atoms and 1 to 2 heteroatoms, lower aryl and lower aralkyl;

R^{12} is selected from the group consisting of $-N(R^{11})_2$, and $-SR^{11}$;

R^{13} is selected from the group consisting of R^{11} , and
20 M;

R^{14} is selected from the group consisting of -H, and $-OR^{10}$, with the proviso that when z is 2, then together the two R^{14} groups may form a double bond;

R^{15} is independently selected from the group
25 consisting of $-R^{11}$ and $-COOH$.

M is selected from the group consisting of Na^+ , K^+ , Mg^{2+} , and Ca^{2+} ;



M' is selected from the group consisting of -H, -M, and R^9 ; and

X is selected from the group consisting of -O-,
-S-, -C(R¹¹)₂-, and -N(R¹¹)-; and pharmaceutically
acceptable salts thereof with the provisos that:


- 5 (a) when any of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are
-Y-B and W is a direct link, then at least one adjacent
position must be -OH or an ether moiety;
- (b) no more than two of R¹, R², R³, R⁴, R⁵, R⁶, R⁷,
and R⁸ may be Y-B when W is a direct link;
- (c) no more than three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷,
10 and R⁸ may be a direct link to A;
- (d) only one of R¹, R⁴, R⁵, and R⁸ may be a direct
link to B;
- (e) when one of R¹, R⁴, R⁵, or R⁸ is a direct link to
B, then at most two of the other naphthyl substituents
15 can be a direct link to A when A is not B;
- (f) at most three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸
may be independently selected from the group consisting
of -OH and ether moieties;
- (g) at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸
20 is -H;
- (h) when any of R¹, R⁴, R⁵, and R⁸ is a direct link
to B, then the adjacent position must -OH or an ether
moiety;
- (i) at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸
25 is a substituent containing a B group, and at least one
is a substituent containing an A group where A is not B;
and
- (j) only when A is directly linked to the naphthyl
structure may A be -(C=O)R¹¹, and when A is -(C=O)R¹¹, at
30 least one adjacent position must be -OH.

2. The compounds as described in claim 1, wherein said compounds are bound to known drugs so as to target the drug-selectin ligand complex to a particular site of disease.


5 3. The compounds of claim 1 wherein at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are independently selected from the group consisting of



10






15




20 $-W(CH_2-CR_{11}(OR^{11})CH_2-B)_t$, -OH, lower alkoxy, lower aryloxy, lower araloxy, lower alkoxyaryl, a direct link to A where A is not B, and a direct link to B; where W is a direct link or -O-, and t is 1.

4. The compounds of claim 3 wherein at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are selected from the group consisting of

25







$-\text{W}(\text{CH}_2-\text{CR}_{11}(\text{OR}^{11})\text{CH}_2-\text{B})_t$, $-\text{OH}$, and a direct link to A where A is not B.

5. The compounds of claim 1 wherein A and B are selected from the group consisting of sialic acid and
10 fucose, respectively.


6. The compounds of claim 1 wherein A is selected from the group consisting of α or β or other analogues or derivatives of sialic acid other than the N-acetyl neuraminic acid residue shown in formula V, Kemp's acid,
15 quinic acid, R and S forms of mandelic acid, R and S forms of glyceric acid, R and S forms of lactic acid, propionic and acetic acid, and esters and amides thereof, $-\text{SO}_3$, and $-\text{PO}_3$:



7. The compounds of claim 6 wherein B is selected from the group consisting of structure VI:



alpha-Form



beta-Form

wherein Me is a methyl group, R^{17} , R^{18} and R^{19} are each independently -OH, -F, $-N(R^9)_2$, wherein R^9 is lower alkyl; corresponding carboxylic analogues of fucose; inositol; substituted inositol; imidazole, substituted imidazole; benzimidazole; substituted benzimidazole; Guanidine; pentaerythritol; substituted pentaerythritol; substituted butane of the formula $-CH_2-CHR^{17}-CHR^{18}CH_2R^{19}$ wherein R^{17} , R^{18} and R^{19} are independently OH, F or $-N(R^9)_2$.

8. The compounds of claim 1 wherein the B group: s is 1 or 2, R^{14} is -H or -OH, X is -O-, U is $-CH_2OR^{10}$ or $-R^9$, and R^{10} is -alk-COOH, $-SO_3M$, -H, or -alk-COOM.

9. The compounds of claim 8 wherein s is 2.

10. The compounds of claim 9 wherein B is selected from the group consisting of fucose, galactose, mannose, and arabinose.

11. The compounds of claim 1 wherein s numbers are 1 and 2.

12. The compounds of claim 11 wherein s is 2.
13. The compounds of claim 1 wherein q numbers are
0 and 1.
14. The compounds of claim 1 wherein m numbers are
5 0 and 1.
15. The compounds of claim 1 wherein n numbers are
0 and 3.
16. The compounds of claim 1 wherein R^{10} is
selected from the group consisting of -H, SO_3M ,
10 -alk-COOR¹³, and -O-carbohydrate.
17. The compounds of claim 16 wherein R^{10} is
selected from the group consisting of -H, $-SO_3M$, and
-alk-COOR¹³.
18. The compounds of claim 1 wherein R^{11} is
15 selected from the group consisting of -H, lower alkyl,
and lower aralkyl.
19. The compounds of claim 18 wherein R^{11} is -H.
20. The compounds of claim 1 wherein R^{12} is
-N(R^{11})₂.
- 20 21. The compounds of claim 1 wherein R^{14} is
selected from the group consisting of -H and -OH.

22. The compounds of claim 1 wherein R^{15} is selected from the group consisting of $-\text{COOH}$, $-\text{H}$, and $-\text{CH}_3$.

23. The compounds of claim 1 wherein M is Na^+ .

5 24. The compounds of claim 1 wherein M' is selected from the group consisting of $-\text{H}$, Na^+ , and $-\text{CH}_3$.

25. The compounds of claim 1 wherein X group is $-\text{O}-$.



26. The compounds of claim 1 wherein U is selected
10 from the group consisting of $-\text{CH}_2\text{OR}^{10}$ and $-\text{R}^9$.

27. The compounds of claim 1 wherein W is selected from the group consisting of a direct link and $-\text{O}-$, and t is 1.

15 28. The compounds of claim 4 wherein at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are independently selected from the group consisting of $-\text{W}(\text{CH}_2(\text{C}=\text{C}(\text{R}^{15})_2)-\text{CH}_2-\text{B}_t$ where W is a direct link or $-\text{OH}$, t is 1, and R^{15} is independently $-\text{H}$, $-\text{CH}_3$, and COOH .

20 29. The compounds of claim 1 wherein R^3 and R^6 are selected from the group consisting of $-\text{SO}_3\text{M}$, $-\text{OSO}_3\text{M}$, $-\text{NO}_2$, and $-\text{CO}_2\text{H}$, and at least one of R^1 , R^2 , or R^7 is selected from the group OH and $-\text{NH}_2$.

30. The compounds of claim 1 wherein R¹ is a direct link to B, R² and R³ are selected from the group consisting of -OH,




10 where W is a direct link and t is 1, R⁷ is selected from the group consisting of -H or -OH, and R⁶ is selected from the group consisting of -H and -(CH₂)_m-(CHR⁹)_q-(CH₂)_n-A, where each m and q are independently selected from 0 or 1, and A is a saturated or
15 unsaturated carboxylic acid of 1 to 4 carbon atoms, optionally substituted with 1 to 2 hydroxy groups, and esters and amides thereof.

31. The compounds of claim 30 wherein the B group
s is 1 or 2, R¹⁴ is -H or -OH, X is -O-, U is -CH₂OR¹⁰ or
20 -R⁹, and R¹⁰ is -alk-COOH, -SO₃M, -H, or -alk-COOM.

32. The compounds of claim 30 wherein R¹⁵ is -H.

33. A method of treating disease in a patient in
need thereof, said disease selected from the group
consisting of cancer, auto-immune disorders, and
25 inflammation, by administration of a pharmaceutically
effective amount of a compound of formula I:





wherein

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are independently selected from the group consisting of

- (a) -H, Y-B, alkyl of 1 to 4 carbon atoms optionally substituted with 1 to 2 lower alkyl groups,
 5 $-W((CH_2)_n-B)_t$, $-W((CH_2)_m-(CHR^9)_q-(CH_2)_m-A)_t$;
 -OH, lower alkoxy, lower aryloxy, lower aralkoxy, lower alkoxyaryl, amino,
 $-W((CH_2)_n-A)_t$, $-O-CH_2-C\equiv C-B$, $-N(Ac)-CH_2-C\equiv C-B$, $-NH-CH_2-C\equiv C-B$, $-N(CH_2-C\equiv C-B)_2$, $-N(Ac)CH_2Ar-B$, $-NHCH_2Ar-B$,
 10 $-N(CH_2Ar-B)_2$, $-OCH_2Ar-B$, $-(C=O)(CH_2)_m-B$,

(b) a direct link to A, and a direct link to B;
 where


- Y-B is selected from the group consisting of
 $-W(CH_2(C=O)CH_2-B)_t$, $-W(CH_2(C=C(R^{15})_2)-CH_2-B)_t$,
 15 $-W(CH_2CH-CH_2-B)_t$, $-W(CH_2CR^{11}-CH_2-B)_t$,
 $\begin{array}{c} | \\ CH(R^{11})_2 \end{array}$ $\begin{array}{c} | \\ C(R^{11})_2OR^{11} \end{array}$



Λ is selected from the group consisting of $-(\text{C}=\text{O})\text{R}^{11}$, sialic acid, Kemp's acid, quinic acid, $-\text{B}$, $-\text{SO}_3\text{M}$, $-\text{OSO}_3\text{M}$, $-\text{SO}_2\text{NH}_2$, $-\text{PO}_3\text{M}_2$, $-\text{OPO}_3\text{M}_2$, $-\text{NO}_2$, saturated or unsaturated carboxylic acids of 1 to 4 carbon atoms, optionally substituted with 1 to 2 hydroxyl groups, and esters, and amides thereof;

W is selected from the group consisting of a direct link, $-\text{O}-$, $-\text{N}-$, $-\text{S}-$, $-\text{NH}-$, and $-\text{NAC}-$;

10 B is



15

wherein

U is selected from the group consisting of $-\text{R}^9$, $-\text{CH}_2\text{OR}^{10}$, $-\text{CH}_2\text{O-protecting group}$, $-\text{COOR}^{11}$, $-\text{CON}(\text{R}^{11})_2$, and $-\text{COOM}$;

- R⁹ is lower alkyl;
each n is independently selected from the group 0,
1, 2, and 3;
each m is independently selected from the group 0,
5 1, 2, 3, and 4;
each q is independently selected from the group 0,
1, and 2;
each s is independently selected from the group 1,
2, and 3;
10 each z is independently selected from the group 1
and 2;
each t is independently selected from the group 1
and 2, with the proviso that when W is $-N<$, then t is
2, and at all other definitions of W, t is 1;
15 R¹⁰ is selected from the group consisting of -H,
-R¹¹, -SO₂M, -(C=O)R¹¹, -SO₂NH₂, -PO₃M₂, -alk-COOR¹¹,
alk-CON(R¹¹)₂, and -O-carbohydrate;
R¹¹ is independently selected from the group
consisting of -H, lower alkyl, cyclic alkyl of 5 to 6
20 carbon atoms, heterocyclic alkyl of 4 to 5 carbon atoms
and 1 to 2 heteroatoms, lower aryl and lower aralkyl;
R¹² is selected from the group consisting of
-N(R¹¹)₂, and -SR¹¹;
R¹³ is selected from the group consisting of R¹¹, and
25 M;
R¹⁴ is selected from the group consisting of -H, and
-OR¹⁰, with the proviso that when z is 2, then together
the two R¹⁴ groups may form a double bond;

R¹⁵ is independently selected from the group consisting of -R¹¹ and -COOH.

M is selected from the group consisting of Na⁺, K⁺, Mg²⁺, and Ca²⁺;

5 M' is selected from the group consisting of -H, -M, and R⁹; and

X is selected from the group consisting of -O-, -S-, -C(R¹¹)₂-, and -N(R¹¹)-; and pharmaceutically acceptable salts thereof with the provisos that:

10 (a) when any of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are -Y-B and W is a direct link, then at least one adjacent position must be -OH or an ether moiety;

(b) no more than two of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be Y-B when W is a direct link;

15 (c) no more than three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be a direct link to A;

(d) only one of R¹, R⁴, R⁵, and R⁸ may be a direct link to B;

20 (e) when one of R¹, R⁴, R⁵, or R⁸ is a direct link to B, then at most two of the other naphthyl substituents can be a direct link to A when A is not B;

(f) at most three of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ may be independently selected from the group consisting of -OH and ether moieties;


(g) at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is -H;

(h) when any of R¹, R⁴, R⁵, and R⁸ is a direct link to B, then the adjacent position must -OH or an ether moiety;

(i) at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 is a substituent containing a B group, and at least one is a substituent containing an A group where A is not B; and

- 5 (j) only when A is directly linked to the naphthyl structure may A be $-(C=O)R^{11}$, and when A is $-(C=O)R^{11}$, at least one adjacent position must be $-OH$.

FIG. 1.






FIG. 2.

INT NATIONAL SEARCH REPORT

International Application No
US 97/02950

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H15/18 C07D309/10 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X A	<p>WO 96 05209 A (GLYCOMED INC) 22 February 1996 see claim 29; examples 18,20-23</p> <p>--- EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol. 3, no. 7, 1 July 1994, pages 709-24, XP000579145 DASGUPTA F; RAO B N N : " ANTI-ADHESIVE THERAPEUTICS: A NEW CLASS OF ANTI-INFLAMMATORY AGENTS " cited in the application</p> <p>--- -/-</p>	1-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search 10 June 1997	Date of mailing of the international search report 16. 07. 97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer Bardili, W

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/US 97/02950

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ATHANASSIOS GIANNIS , vol. 106, no. 2, 1 January 1994, pages 188-91, XP000570918 ATHANASSIOS GIANNIS : " DIE SIALYL-LEWIS-X-GRUPPE UND IHRE ANALOGA ALS LIGANDEN FÜR SELEKTINE: CHEMOENZYMATISCHE SYNTHESSEN UND BIOLOGISCHE FUNKTIONEN "</p> <p style="text-align: center;">---</p>	
A	<p>WO 95 05182 A (GLYCOMED INC) 23 February 1995 see examples 9-11</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/US 97/02950

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9605209 A	22-02-96	AU 3325995 A	07-03-96
		CA 2197336 A	22-02-96
		EP 0775151 A	28-05-97
WO 9505182 A	23-02-95	AU 7520394 A	14-03-95

THIS PAGE BLANK (USPTO)